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Abstract
Introduction: Magnetic resonance (MR) guided radiation therapy (MRgRT) is
an emerging field that integrates an MR imager with either a linear accelerator or three
radioactive cobalt-60 sources. Before institutions participate in multi-institutional NCIsponsored clinical trials, they are required to perform a credentialing test provided by
IROC-Houston. During the credentialing test, end-to-end phantoms are used to evaluate
the institution’s ability to perform consistent and accurate radiation treatments. IROCHouston’s conventional anthropomorphic phantoms are not visible in MR, thus they are
insufficient for MRgRT systems. The purpose of this work was to create an
anthropomorphic thorax and a head and neck (H&N) phantom for MRgRT systems
with magnetic fields ranging from 0.35T to 1.5T.
Methods: Over 80 synthetic materials were examined as potential materials
used to construct the MRgRT thorax and H&N phantoms. Materials were characterized
by: 1) measuring Hounsfield units, 2) visualizing in MR and CT imagers and 3)
evaluating their dosimetric characteristics. Once materials were selected for the
MRgRT phantoms, radiochromic film and double-loaded TLDs were then characterized
in a 1.5T and a 0.35T MR environment. Reproducibility measurements on doubleloaded TLDs were performed by using an acrylic block and irradiating it in 0T/1.5T
and 0T/0.35T configurations on the Unity system and the MRIdian Cobalt 60 system,
vii

respectively. Geometrical thorax and H&N phantom slabs were designed to mimic
similar interface conditions seen in anthropomorphic phantoms, but were simplified to
reduce manufacturing time. The geometrical phantoms were designed with a
rectangular tumor centrally located around surrounding tissue. These two phantoms
were used to characterize radiochromic EBT3 film and TLDs by comparing beam
profiles and point dose measurements irradiated with and without magnetic fields,
respectively. GEANT4 Monte Carlo simulations validated the detectors in both Unity
0T/1.5T and MRIdian 0T/0.35T configurations. Two MRgRT anthropomorphic (H&N
and thorax) phantoms were designed, manufactured and evaluated. A reproducibility
and feasibility study was conducted to evaluate the phantom’s performance on MRgRT
systems.
Results: This study found four materials which were tissue equivalent and
visible on both MR and CT. Additionally, this study showed negligible difference in
dose response between TLDs and radiochromic film when irradiated in 0.35T and 1.5T
magnetic field environments. Two anthropomorphic phantoms were constructed and
evaluated. The anthropomorphic thorax and H&N phantoms passed IROC-Houston’s
7%/5mm and 7%/4mm gamma passing criteria, respectively.
Conclusions: An anthropomorphic thorax and an H&N phantom were tissue
equivalent, compatible with MR and CT workflows and could be used as end-to-end
QA tools for MRgRT systems with magnetic fields ranging from 0.35T to 1.5T.
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Chapter 1:

1.1
1.1.1

Introduction

BACKGROUND
Imaging Guidance in Radiation Therapy
Most modern radiotherapy systems are equipped with image-guided radiotherapy

(IGRT) devices to verify patient setup and manage intrafraction and interfraction
motion1-3. IGRT devices can broadly be categorized into either radiation or non-radiation
based systems. Some radiation-based systems include: electronic portal imaging device
(EPID), Computed Tomography (CT) on rails, Megavoltage CT (MVCT), and cone beam
CT (CBCT); common non-radiation based IGRT devices are ultrasound and camerabased systems. Modern treatment vaults can be equipped with either a single IGRT
system or multiple IGRT systems used in conjunction with one another.
Gantry-mounted electronic portal imaging systems, commonly known as EPID
systems, are equipped with a flat-panel imager mounted parallel to an in-field linear
accelerator. These systems are used to verify patient setup from the treatment field’s
orientation by capturing a single two-dimensional (2D) MV image. Modern EPID
systems are readily available since they use the same beam path and energy as the linear
accelerator. Compton interaction dominates during MV imaging. Consequently, these 2D
images produce poor contrast between tissues that have similar effective atomic numbers
(Zeff)4. Structure interfaces that have large Zeff deviations, such as bony anatomy or
fiducial markers next to soft tissue, will have high contrast delineation in MV images.
Therefore, EPID images are primarily used to verify patient setup by comparing gross
anatomy (i.e., bony anatomy) to CT images. While EPID systems are convenient and use
1

the same photon beam, they are a limiting IGRT system since they mostly are used to
align rigid structures. EPID systems (unless imaged multiple times) are also limited since
they only capture a 2D image at a single point in time.
Another IGRT system, known as MVCT, captures a three-dimensional (3D)
image by using an in-field MV beam parallel to a fan beam detector. Helical
TomoTherapy is the most commonly known MVCT system used in the clinic and was
specially designed to alleviate 2D setup errors. During imaging acquisition, the beam
energy is reduced from 6 MV to 3.5 MV and both detector and beam rotate around a
single isocenter as a treatment couch travels through the bore. The reduced beam energy
allows for greater soft tissue contrast compared to a normal 6 MV image and eliminates
streaking artifacts caused in lower KV images5. While MVCT soft tissue contrast is
enhanced, acquired images have poor delineation between tumor and surrounding
tissues. Additionally, MVCT requires more time to acquire an image and can only
capture a single-frame image6.
To produce diagnostic-quality images, a conventional CT can be installed inside
the treatment vaults. Commonly referred to as, CT on rails, a treatment couch is rotated
180 degrees where a mobile diagnostic CT scanner slides across a pair of rails and
captures a 3D image which is then used to verify patient setup3. Diagnostic-quality 3D
CT images permit better soft tissue contrast than MV generated images, thus improving
soft tissue localization. CT on rails has a few limitations: 1) images are only captured pre
or post treatment, 2) large vaults are required to hold both systems, and 3) CT on rails is
incapable of tracking intrafraction motion.
CBCT is currently a popular IGRT system which is typically mounted onto the
treatment gantry and installed orthogonal to the treatment beam. This system is equipped
2

with a retractable x-ray tube parallel to a flat panel imager7. KV energies are used to
acquire a single-frame volumetric image by rotating the gantry around the treatment
couch2-4. CBCT images produce superior soft tissue contrast compared to common MV
IGRT systems. While CBCT is currently considered the most universal 3D IGRT system
used for pre-treatment setup verification, there are limitations prevent CBCT from being
the absolute universal IGRT system3. The cone beam geometry in CBCT contributes to
larger radiation scatter which consequently affects the image quality. Therefore,
diagnostic-quality CT images are not captured in CBCT imagers. This degrade in image
quality can impair soft-tissue delineation that is required to accurately verify treatment
setup. Similar to other IGRT systems, CBCT is limited to only capturing a single-frame
image and is unable to track intrafraction motion without capturing multiple images that
would then increase patient dose.
Ultrasound imaging can also be used as an IGRT system for radiotherapy. Inroom ultrasound image guidance is inexpensive, non-ionizing and is used as a sitespecific tumor localization method. Ultrasound captures a 2D image which is used to
localize soft tissue organs such as a liver, a breast or a prostate. In-room ultrasound image
guidance verifies patient setup by mapping a 2D ultrasound image to the treatment
room’s coordinate system3-5. Other than being restricted to soft tissue organs, there are
two limiting factors: 1) inter-user variability and 2) the inability to capture real-time
images4; 5. Ultrasound images are hard to reproduce since the acquisition is highly
dependent on the transducer’s angle relative to the patient. Secondly, images are not
captured during treatment since these systems are not automatized and therefore require
a sonographer to operate the equipment. Since the transducer is required to be close to
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the patient, any automated system would generally be within the treatment field and
ultimately might alter the dose deposition.
Camera-based systems are another non-ionizing radiation imaging technique.
These systems are used to verify setup positions through visible or infrared cameras. Inroom camera based systems are relatively cheap to install and have a live feedback
mechanism used to correct setup errors occurring at any point during treatment7. Some
of these systems are used for site specific locations. These systems mostly commonly are
used to account for intrafraction motion by implying either gating or external surrogating
techniques. The major limitation of camera-based systems is the lack of visualizing
internal structures such as the disease site and surrounding normal tissues. Camera-based
systems assume exterior surface motion directly correlates with tumor motion. For some
tumors, measured surface movements do not accurately resemble the same motion a
tumor experiences. Inability to visualize internal soft tissues prevents the system from
accurately track tumor motion, and internal organ deformations7; 8.

1.1.1.1 Benefits of On-board MR imaging
Current IGRT systems have greatly improved dose delivery accuracy in radiation
therapy by reducing interfraction setup errors; however, these systems all have
limitations that either are incapable of distinguishing the disease site from surrounding
normal tissue, visualizing the tumor in real-time or capturing images to be used for online
adapted radiotherapy. Recently, there have been attempts to mitigate these limitations by
integrating a magnetic resonance (MR) system with either a linear accelerator or a
radioactive cobalt 60 source. MR provides superior soft tissue contrast compared to
images acquired from either KV or MV imagers. This improved ability to visualize soft
4

tissue would consequently increase the accuracy of delineating the tumor boundary from
normal tissue (Figure 1)9. Better target delineation could be used to reduce margins or
increase the gross tumor volume (GTV) radiation boost, which could potentially increase
local tumor control and reduce normal tissue toxicities. Another advantage is that MR
does not contribute to the absorbed dose; so, a patient is not restricted to a single-frame
setup image but rather could be image during the entire treatment. Fast sequence
protocols used in on-board MR scanners enable 2D and 3D cine images during treatment.
This eliminates the need for external surrogates and improves gating techniques by
tracking the disease site in real-time. Online adapted radiotherapy could be implemented
in the clinic since images with superior contrast would be used to localize the disease
site. The newly captured MR image would then be used to adjust the treatment plan to
the disease site’s current location. On-board MR imagers could potentially be used to
capture functional imaging information which then could be used to quantify and
evaluate the overall tumor progression during treatment. Therefore, on-board MR
imagers could revolutionize radiation treatment by improving the certainty of delivering
radiation.

Figure 1: A comparison between abdominal images captured on a 0.35T on-board MR
imager (left) and CBCT (right). The low field MRI provides high soft tissue contrast to
distinguish between a pancreas tumor and surrounding organs, whereas the CBCT shows
insignificant contrast between the two9.
5

1.1.2

MR guided Radiation Therapy Systems

Magnetic resonance guided radiotherapy (MRgRT) is a rapidly emerging field
which integrates a fully functional MR imager in conjunction with either a linear
accelerator or a radioactive Cobalt 60 (60Co) source. Presently, there are a total of six
different MRgRT prototypes: two are still in the research stage and four have been fully
implemented into the clinic10-16. Pre-clinical MRgRT systems are: the Australian MRLinac (Ingham Institute, Liverpool, Australia) and Aurora RT (MagnetTx Oncology
Solutions, Alberta, Canada) and clinically implemented MRgRT systems are: MRgRT
suite (Varian, Palo Alto, California, USA and Siemens, Erlangen, Germany), Unity
(Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands). MRIdian 60Co
(ViewRay, Oakwood Village, Ohio), and MRIdian Linac (ViewRay, Oakwood Village,
Ohio).
In short, the Australian MRI-Linac is an inline MRgRT system equipped with a
6 MV linear accelerator and a 1.0 T open bore magnet11. This system was designed to
have a fixed 6 MV beam with a mobile treatment couch that was capable of rotating 360
degrees inside the bore11; 17. The Aurora RT system was first designed to have a 6 MV
beam only; however, additional research has been performed to create a versatile MRgRT
system that has four possible (4 MV, 6 MV, 8 MV and 10 MV) discrete energies13; 18-20.
This system was designed such that a linear accelerator can rotate around a biplanar 0.5T
magnet, thus allowing a photon beam to transmit in either parallel or perpendicular
directions from the magnetic field13; 21. The first MRgRT system used to treat patients
was developed at the Princess Margaret Cancer Centre and is commonly known as the
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MRgRT suite. This suite interconnects three rooms which allow a Siemen’s MRI on rails
system to travel to either a Varian TrueBeam vault or a Nucletron brachytherapy suite10.
Elekta’s Unity system started treating patients in 2017 and is equipped with a 7 MV linear
accelerator located above a modified 1.5T Philip’s MR scanner. The ViewRay system
currently has two models: ViewRay MRIdian and ViewRay MRIdian Linac, both of
which are FDA cleared and have been fully implemented into the clinic to treat patients.
The MRIdian system, which started treating patients in 2014, is equipped with three 60Co
radioactive head sources located in between a split 0.35T magnet. The MRIdian Linac,
which started treating patients in 2017, is a modification to the original

60

Co MRIdian

system22. In this upgraded MRgRT system, the three radioactive sources were replaced
with a single 6 MV beam. Table 1 is a summary of all MRgRT systems and their technical
specifications.
While there are several different emerging MRgRT devices (Table 1), the only
systems currently used within the United States are the Elekta/Philip’s Unity, the
ViewRay’s MRIdian

60

Co, and the ViewRay’s MRIdian Linac MRgRT system. Both

MRIdian and Unity systems are capable of intrafractional and interfractional monitoring,
cine images during treatment, and adaptive radiation therapy15; 23. These systems were
used to develop and characterize the Imaging and Radiation Oncology Core Quality
Assurance Center in Houston’s (IROC-Houston) MRgRT QA phantoms. These three
MRgRT systems’ configurations will further be discussed in the following subsections.
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Energy

Magnetic
Field
Strength

Bore
Diameter

Beam
Direction to
Magnetic
Field

First
Treated
Patients

Australian
MRI-Linaca

6 MV

1.0T

82 cm

Parallel or
Perpendicular

n/a

Aurora RTb

4, 6, 8
and 10
MV

0.5 T

60 cm

Parallel or
Perpendicular

n/a

MRgRT
Systems

2014
MRI on
Railsc

6 MV

1.5T

70 cm

n/a

Unityd

7 MV

1.5T

70 cm

Perpendicular

(UMC Utrecht,
Netherlands)

MRIdiane

3 Co-60

0.35T

70 cm

Perpendicular

(Washington
University,
USA)

MRIdian
Linace

6 MV

(Princess
Margret
Cancer Centre,
Canada)

2017
2014

2017

(Henry Ford
Health Systems,
USA)
a: Ingham Institute, Liverpool, Australia b: MagnetTx Oncology Solutions, Alberta, Canada c: Varian, Palo Alto,
California, USA and Siemens, Erlangen, Germany d: Elekta, Crawley, United Kingdom and Philips, Amsterdam,
Netherlands e: ViewRay Oakwood Village, Ohio, USA

0.35T

70 cm

Perpendicular

Table 1: Summary of the current MRgRT systems. Among all MRgRT systems, two are in
the clinical development stage (Australian MRI-Linac and Aurora RT) and four have been
used to treat patients (MRI on Rails, Unity, MRIdian, and MRIdian Linac).

1.1.2.1 Elekta Unity System
The Unity system was equipped with a flattening filter free (FFF) 7 MV standing
waveguide attached to a slip ring gantry centrally located above a modified 1.5T MR
system (Figure 2). The magnet was redesigned to have a 15 cm gap free of coils in the
center of the magnet. Additionally, active shielding was modified to create a low field
toroidal (<10-3T magnetic field) in the center of the magnet24; 25. The 7 MV linear
accelerator was centrally installed above the magnet, where both systems could be
magnetically decoupled from one another. The MR component works independently of
the linear accelerator and can be used to capture real-time diagnostic-quality 2D and 3D
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images at 8 frames per second. The linear accelerator was designed to have a 160-leaf
multi-leaf collimator (MLC) system and could be extended to have a maximum field size
of 57 cm (sagittal) by 22 cm (axial) 23; 26. The Unity system is presently not FDA cleared
to treat patients in the United States; however, the first patient treated on the Unity system
was at The University Medical Center Utrecht in 201723.

Figure 2: Elekta’s Unity system, which is the first high magnetic field (1.5T)
system integrated with a 7 MV linear accelerator.

1.1.2.2 ViewRay MRIdian System
The ViewRay MRIdian is the first single-room integrated MRgRT system to
simultaneously treat and image patients. The MRIdian system was FDA cleared in 2012
and began treating patients in 2014. The MRIdian system (Figure 3) delivers modulated
radiation therapy using three independent 60Co head sources equally spaced 120-degrees
from each other. The radioactive sources are centrally located in between a split 0.35T

9

superconducting magnet27. All three

60

Co head sources simultaneously rotate 240-

degrees around a ring gantry to provide 360-degree coverage and can be used
individually or simultaneously with one another. The head sources can be used together
to provide a dose rate comparable to a typical 6 MV linear accelerator (550 cGy/min at
installation) 15; 28. Each source was equipped with a 60 leaf double-focus MLC to provide
comparable penumbras that are typically seen in a 6 MV linear accelerator15; 28. Using
radioactive head sources in between a split magnet eliminated the need for electronics,
which allowed the two systems to work independently of one another.

Figure 3: ViewRay’s first MRgRT system. The MRIdian Co-60 is comprised of three
equally spaced cobalt 60 head sources centrally located in between a spilt 0.35T
semiconducting magnetic. In 2014, the first patient was treated on the MRIdian Co-60
system at Washington University School of Medicine in St. Louis, Missouri, USA27.

The MRIdian Linac (Figure 4) is an upgraded MRgRT system that replaced three
radioactive

60

waveguide29;

Co sources with a single compact inline S-band 6 MV standing

30

. Similar to ViewRay’s first generation MRgRT system, the linear

accelerator is centrally located in between a split 0.35T superconducting magnet. The
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compact linear accelerator is enclosed around a magnetic and RF shield, thus allowing
the two systems to work independently of each other30. The FFF linear accelerator was
designed to produce dose rates greater than 600cGy/min and was constructed with 138leaf double-focused double-stacked MLC system. The two sets of MLC are used to create
a sharp penumbra and to reduce interleaf leakage30. The MRIdian Linac was granted
FDA clearance in early 2017 and started treating patients that summer22.

Figure 4: ViewRay’s upgraded MRgRT system. The MRIdian Linac is comprised of a 6 MV
linear accelerator centrally located in between a spilt 0.35T semiconducting magnetic. The
first patient treated on the MRIdian Linac was in 2017 at Henry Ford Health Center, Gross
Point, Michigan, USA29.

Both MRIdian and MRIdian Linac systems use a Monte Carlo based treatment
planning system known as the ViewRay System Treatment Planning and Delivery
Software (VR-TPDS). The VR-TPDS is capable of creating 3D conformal radiation
therapy (3D-CRT), intensity modulated radiation therapy (IMRT), stereotactic body
radiation therapy (SBRT), stereotactic radiosurgery (SRS) and IGRT plans. At 4 frames
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per second, both systems can acquire a single sagittal image using a single true fast
imaging with a steady state precession MR sequence31.
1.1.3

Dosimetric Challenges in MRgRT systems
Secondary electrons, set into motion from photon interactions, are affected by

magnetic field environments. This phenomenon can be explained by the Lorentz force
(Equation 1). When charge particles (q) with a velocity (v) experience a magnetic field
(B), the Lorentz force causes the charge particle’s trajectory to curve perpendicularly
from the magnetic field direction and velocity direction.
𝑭 = 𝑞(𝒗 × 𝑩)

(Eq.1)

The magnetic field affects the trajectories of secondary electrons which, specific
to radiotherapy, will consequently affect dose being deposited into a tissue. Figure 5
visually describes how a single electron’s point spread kernel is affected in different
magnetic field strengths perpendicular to a 6 MV photon beam inside a homogenous
water phantom32. In low magnetic field environments (i.e., 0.2T), the electron’s trajectory
is generally unaffected by the magnetic field and creates similar radiation deposition seen
in zero magnetic field environments. In high field environments (i.e., 3.0T), the electron’s
trajectory is greatly influenced by the magnetic field and, as a result, deposits dose in an
arc-shape pattern. The radius of an electron’s arc-shape trajectory is proportional to the
electron’s energy and inversely proportional to the experienced magnetic field strength32.
Therefore, the point spread kernels are more asymmetrically pronounced for higher
magnetic fields and lower electron energies.
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Figure 5: Point spread kernels for a single electron trajectory in a homogenous medium
under a 6MV beam perpendicular to (a) 0T, (b) 0.2T, (c) 0.75T, (d) 1.5T and (e) 3T magnetic
field strengths. Point spread kernels become more asymmetric in larger magnetic field
environments32.

Secondary electrons traveling through heterogeneous materials in the presence of
a magnetic field will experience what is known as the electron return effect (ERE). The
ERE is most prominent at interfaces with high density variations such as: air cavities or
patient exteriors. As the electron exits from a higher-density material and enters into a
lower-density material, the electron will curve back into the high-density material and
deposit dose (Figure 6). In Monte Carlo studies, dose deposited in complex
heterogeneous systems generally showed that the dose decreased in low-density to highdensity interfaces but increased in high-density to low-density interfaces33. Further
investigation also showed that, at first order, opposing photon beams could
counterbalance the ERE effect in heterogeneous materials33.

13

Figure 6: A single electron trajectory propagating through high to low density medium in
absence (left) and presence (right) of a magnetic field34.

High magnetic field can also affect general radiation beam characteristic, namely,
percent depth dose (PDD) curves and beam profiles. In general, the secondary electron’s
helical-shape trajectories reduce the overall path, causing the PDD to shift. Specifically
in a 7 MV photon beam perpendicular to a 1.5T magnetic field configuration, the PDD
is modified causing a shorter build-up region, a 4-5 mm shift in the depth of maximum
dose (dmax) towards the surface, and an approximately 0.5% reduction in dose beyond
build up region (Figure 8)35; 36. In the presence of a 1.5T magnetic field, the output at
dmax is enhanced by 1.9%36. For a 7 MV beam the dmax was measured at 1.3 cm and
1.7 cm for 1.5T and 0T configurations, respectively36.
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Figure 7: Geant4 Monte Carlo measurements comparing PDD curves under the presence of
0T and 1.5T magnetic field strengths for a 7 MV photon beam with a 10x10 cm2 field size35.

Magnetic fields also affect beam profiles by creating asymmetric dose deposition
in the lateral direction. The entire field, towards the Lorentz force direction, shifts
approximately 1 mm for all field sizes at the 50% level35; 37. A more dramatic shift was
seen in the shoulder region of the profiles due to the magnetic field influence. As shown
in Figure 8, the general shape of beam profiles measured in a 1.5T magnetic field are
asymmetric and more pronounced in smaller field sizes. From the central axis, the
disproportional penumbras are less pronounced on the right side and vice versa, more
pronounced on the left side due to the effects of the magnetic field. In general, smaller
fields (1x1cm2) are affected more by a magnetic field than larger field sizes (i.e., 10 x
10cm2)32.
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Figure 8: GEANT4 Monte Carlo generated beam profiles for a 6 MV radiation beam
incident perpendicular to 1.5T and 0T magnetic field strengths for 1.0 cm x 1.0 cm2 and 5.0 x
5.0 cm2 field size34.

1.1.4

Conventional IROC Phantoms
IROC-Houston, formally known as Radiological Physics Center or RPC, has

been funded by the National Cancer Institute (NCI) since 1968 to help credential and
audit institutions participating in NCI sponsored clinical trials. IROC monitors NCI
participating institutions’ performances through either on-site dosimetry visits or off-site
auditing methods.
Among various off-site quality assurance (QA) programs, IROC-Houston
implemented an anthropomorphic program designed to evaluate multi-institutions’
performances through an end-to-end examination. The main purpose of this off-site QA
program was to ensure that all institutions participating in NCI clinic trials could deliver
comparable and consistent radiation treatments. During the examination, the
anthropomorphic phantom will experience the same clinical workflow (i.e., CT imaging,
treatment planning, treatment setup, and dose delivery) as a patient, thus analyzing the
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institution’s capability of delivering radiation based on their expected treatment plan.
IROC-Houston’s current site-specific phantoms used in photon beams include: SRS
Head, IMRT Head and Neck (H&N), IMRT Thorax, 3D CRT Thorax, IMRT Spine, liver
and pelvis/prostate. Most of IROC-Houston’s phantoms are similarly designed consisting
of a water-fillable shell and a removable insert which contains: dosimeters, tumor targets
and organ(s) at risk (OAR) structures.
IROC-Houston’s most widely used phantoms are the H&N and thorax
anthropomorphic phantoms and are, respectively, visualized in Figure 10 & Figure 9.
The materials used to manufacture these phantoms are described in Table 2. In short, the
H&N phantom insert consists of an acrylic spinal cord representing an OAR, surrounding
tissue constructed of high impact polystyrene (HIPS), and two (primary and secondary)
planning target volumes (PTV) constructed from solid water. The thorax phantom utilizes
a programmable stepper motor to reflect normal inhale/exhale physiology and consists
of an acrylic spinal cord, nylon heart, two lungs constructed from compressed cork, and
HIPS representing a PTV centrally located inside the left lung. Substituted materials used
in the H&N and thorax phantoms are tissue equivalent and have similar density as
corresponding human tissues (Table 3).

Structure

H&N Materials

Thorax Materials

Tumor

Solid Water

HIPS

Surrounding Tissue

HIPS

Compressed Cork

OAR: Spinal Cord

Acrylic

Acrylic

OAR: Heart
n/a
Nylon
Table 2: Material assigned to IROC-Houston’s conventional thorax and H&N phantom.
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Figure 9: IROC-Houston’s water-fillable anthropomorphic lung phantom contains a nylon
heart, an acrylic spinal cord, two compressed cork lungs and a centrally located HIPS tumor
inside the left-side lung. The left-sided lung is created from an external insert that is
mounted to a motion table to simulate breathing.

Figure 10: IROC-Houston’s conventional H&N phantom is constructed using solid HIPS
and is equipped with a centrally located single insert. The insert has two parts that combine
to create an acrylic spinal cord, a semi-circle primary PTV and a circular secondary PTV
constructed of solid water.
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Material

Density
[g/cm3]

Acrylic

1.17

Compressed Cork

0.33

HIPS

1.20

Nylon

1.08

Solid Water
1.04
Table 3: Density of substituted materials used in IROC-Houston’s conventional H&N and
thorax phantoms.

1.1.5

Detectors used in IROC Phantoms
IROC-Houston’s anthropomorphic phantoms use thermoluminescent detectors

(TLD) and radiochromic film. The measured doses on these detectors are compared with
the expected treatment planning data. In total, eight double-loaded TLDs and three planar
films were inserted into the H&N phantom. Similarly, the thorax phantom was equipped
with four double-loaded TLDs and three planar films. TLDs are used as an absolute point
dose measurement at a specific location and radiochromic films are used to describe
planar relative dose distributions across a specific region within the insert.

1.1.5.1 Thermoluminescent Detectors
Thermoluminescent (TL) is a phenomenon in which inorganic crystals absorb
radiation energy and proportionally emit energy in the form of light when heated. The
generally accepted TL model theorizes that the impurities from the inorganic crystal
causes electron traps in the forbidden energy bands38. These energy traps are located in
between the “allowable” conduction (excited state) and valence (ground state) energy
bands. When an inorganic material is irradiated, electrons in the ground state can absorb
enough energy to rise to the excited state; thereby creating a vacancy (knowns as a
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positive hole) in the ground state (Figure 11). Both excited electrons and positive holes
move around in the conduction and valence bands until they recombine, respectively.
Recombination can occur in two ways: 1) the excited electron can recombine with the
positive hole in the ground state or 2) the excited electron and positive hole can get
“trapped” respectively in an electron trap and hole trap38; 39. When the inorganic crystal
is heated, electrons and positive holes receive enough energy to excite out of their traps,
recombining and emitting one light photon per recombination39. The light photon is
converted into an electrical current through a photomultiplier tube, and then read out.
The intensity of light photons emitted is a function of temperature and is displayed on a
glow curve. Figure 12 shows a typical example of a glow curve for TLD-100s. The area
under the glow curve represents the signal which is the total number of light photons
emitted39.

Figure 11: The physics behind TL phenomena. Impurities in lithium fluoride doped with
magnesium and titanium (LiF: M, Ti) structures create positive hole and electron traps (a).
When radiation passes through a TL structure, the electrons will be excited to a higher energy
state and will leave holes in the valence band. Both holes and electrons will move around the
valence and conduction bands, respectively, until they are either recombined or trapped (b). The
electrons and holes are trapped until a source of heat simulates the structure. Heat energy is
transferred to the electrons and holes thereby releasing them from their traps and allowing for
them to recombine (c). Energy is conserved in the recombination process. The excess energy is
released in the form of a visible light photon.
20

Figure 12: Typical Glow Curve for a TLD-100. The intensity represents the total light
emitted as the material is heated40.

Dose measurements from TLDs can be converted into absorbed dose by applying
several correction factors to the average TL response from photomultiplier readout. Some
of these correction factors include: system sensitivity, dose-response linearity, fading and
energy response. System sensitivity correction factor accounts for the readout system.
Since TLDs are linear up to 4 Gy, a linearity correction factor is used to account for
superlinearity corrections at higher doses. At shallow traps, electrons and holes may
recombine at room temperature and can “fade” the signal. Fading corrections are a factor
of time and are implemented to account for reductions in the signal from irradiation time
to read-out time.
The most extensive TLDs used in radiation therapy are TLD-100s and are
composed of lithium fluoride (LiF) and doped with titanium (Ti) and magnesium (M).
TLD-100s are popular clinical dosimeters since they are nearly tissue equivalent
(effective atomic number of: 6.06) and have deep traps which prevent extreme fading39;
41

. Impurities, caused from doping with Ti and M, allow for trap structures. TLDs can
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come in various forms (i.e., powder, rod, chip, and disk). IROC-Houston purchases
powder-form TLDs (ThermoFisher Scientific, Waltham, Massachusetts, USA) which
come in cylindrical capsules that have a 4 mm diameter and 15 mm length. Doubleloaded TLDs are filled with approximately 22 mg of LiF: M, Ti and is produced with no
air gaps inside the TLD capsule. These TLDs have a linear range of 10 µGy to 1 Gy and
provide two absolute point dose measurements. Previous studies, concluded by Kirby et
al. 1992, showed TLDs to have a 3% precision and a dosimetrically accuracy of 5% (at
93% confidence interval) compared to measured ion chambers readings42.

1.1.5.2 Radiochromic EBT3 Film
In addition to TLDs, IROC-Houston inserts radiochromic film into
anthropomorphic phantoms to analyze the relative 2D radiation dose distributions.
Currently, IROC-Houston uses GafChromic EBT3 (International Specialty Products
Ashland Inc., Covington, Kentucky, USA) film for all anthropomorphic phantom studies.
As shown in Figure 13, EBT3 film is manufactured with three main layers. A thin active
layer (28µm) is located in between two transparent, matte polyester base sheets each
having 125µm thickness. The two identical polyester base sheets that are directly
attached to the active layer prevents the user from keeping track of what side the film
was placed on the light source of a densitometer. According to the manufacturer, the
active layer is comprised of marker dye, stabilizers, active component and aluminum
oxide to minimize low-energy dependence43; 44. EBT3 is nearly tissue equivalent with
an effective atomic number of 6.71 and is generally used to measure radiation dose from
0.01Gy to 10Gy43. EBT3 film is extremely useful for IROC-Houston since it can easily
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be modified to fit inside an insert, does not require wet-post-processing methods, and is
nearly insensitive to light.

Matte Polyester Base Sheet: 125µm
Active Layer: 28µm
Matte Polyester Base Sheet: 125µm

Figure 13: Cross-section describing Gafchromic EBT3 film component layers. Two 125µm
polyester base sheets protecting a 28µm active layer.

1.1.6

Dosimetric End-to-End Evaluations
Gamma Analysis, first developed by Low et al. 1998, is a quantitative method

which compares two distributions (calculated treatment planning dose distribution vs.
measured dose distribution) using a point-by-point methodology. Specifically, this
technique uses 3D spatial coordinates to align the two dose distributions and phantom
dimensions to perform the comparison. The gamma comparison is a measure of the
agreement in dose distributions (DD) considering dose delivered (percent difference
criterion) and position of the dose [distance to agreement (DTA) criterion]. The percent
criterion dominates in regions of shallow to no dose gradient, whereas the DTA criterion
applies to dose distribution areas where there are steep dose gradients. IROC-Houston’s
common evaluation criterion for H&N is 7% dose delivery and 4mm DTA (also written
as 7%/4mm) and for the thorax phantom is 7%/5mm. During evaluation the normalized
gamma-index (γ) will measure the smallest length between the reference point and the
evaluation distributions. If the smallest length in the voxel is >1 (i.e., γ<1), then it said to
be outside the assigned normalized criterion. Vice versa, if the smallest length is <1 (i.e.,
γ>1), then it is within the criteria tolerance. The distributions of all γ values are
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collectively used as a composite to determine whether the measured dose passes or fails
the gamma analysis. This means that for each point in the measured volume, the
measured dose must closely agree with the expected dose to within 7% or it must be
nominally within 4mm of a point dose. For IROC-Houston’s H&N phantom, film is said
to have a gamma passing rate when at least 85% of pixels have γ>1 for sagittal and axial
film dose distribution. Similarly, IROC-Houston’s thorax phantom was said to pass if
the individual axial and sagittal films had at least 80% of pixel passing and if the
combined films had greater than 85% of pixels passing.
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1.2

STATEMENT OF PROBLEM
The NCI requires participating institutions that intend to use IMRT techniques to

first become credentialed by demonstrating their ability to accurately deliver radiation45;
46

. IROC-Houston has developed various site-specific anthropomorphic phantoms that

are used to credential participating institutions. These phantoms were designed as endto-end QA tests used in a traditional radiotherapy workflow. To complete an end-to-end
test, the institution was required to capture a CT image, create an individual treatment
plan based on IROC-Houston’s dose criteria, and irradiate the phantom using a
conventional linear accelerator. IROC-Houston’s conventional phantoms are insufficient
end-to-end QA tools for MRgRT systems.
Unlike conventional linear accelerators, MRgRT systems use MR images to verify
treatment setup, treatment guidance and online adapted radiotherapy. Using one phantom
to perform an end-to-end test means the phantom must be used and visualized in both CT
and MR imagers. IROC-Houston’s current phantoms are constructed of rigid materials
that lack MR signal. Consequently, the lack of signal causes the tumor and surrounding
tissue to be indistinguishable (Figure 14).

With future developments of MR-only

workflows, IROC-Houston’s phantoms must be visible in MR to be used for end-to-end
tests. Therefore, new MRgRT phantoms must be constructed with tissue equivalent
materials that are visible in both CT and MR imagers.
The goal of this project was to create two anthropomorphic phantoms, one being
a homogenous H&N phantom and the other being a motion enabled heterogeneous
thoracic phantom. These phantoms were designed for MRgRT systems that have a
magnetic field ranging from 0.35T to 1.50T. The two phantoms will be used as remote
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end-to-end auditing tools to credential institutions wishing to use MRgRT systems in
NCI-sponsored clinical trials.
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1.3

HYPOTHESIS AND SPECIFIC AIMS
Hypothesis: A homogeneous head and neck (H&N) and dynamic heterogeneous

thoracic anthropomorphic phantom can be designed to evaluate MRgRT which will
assure agreements between the measured and calculated doses within ±7%/4mm and
±7%/5mm, respectively.

Specific Aim 1:
Identify synthetic tissue substitutes that are visible in MR, share common tissue
equivalent properties in CT and are accurately modeled in a treatment planning system.
Specific Aim 2:
Characterize radiochromic EBT3 film, and thermoluminescence detectors (TLD)
in the presence of a magnetic field and validate the detector characterizations using a
Monte Carlo model.
Specific Aim 3:
Design and construct a homogeneous H&N and a dynamic heterogeneous thoracic
anthropomorphic QA phantom; which will be used to verify the dose delivery with the
characterized dosimeters while under the presence of a magnetic field ranging from
0.35T to 1.50T.
Specific Aim 4:
Conduct a feasibility study for the homogeneous head and dynamic heterogeneous
thoracic anthropomorphic phantoms while under the presence of 0.35T and 1.50 T
magnetic field strengths.
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1.4

BENEFITS TO SCIENCE
End-to-end tests are performed with IROC-Houston’s phantoms to ensure all NCI

participating institutions are delivering radiation accurately and in a comparable manner.
Implementing MR into the clinical workflow will require new CT/MR visible
anthropomorphic H&N and thorax phantoms. These specially designed MRgRT QA
phantoms will be used as tools to credential institutions wishing to use MRgRT systems
in NCI-sponsored clinical trials. MR/CT visible phantoms will be used to benefit the
advancement of radiotherapy in two ways: 1) ensuring safe radiation delivery using
MRgRT systems and 2) contributing to the general understanding of the
advantages/disadvantages of MRgRT systems.
A single QA device must be used to evaluate the overall treatment workflow in
MRgRT systems. MRgRT systems have altered the conventional radiotherapy workflow.
On-board MR imagers in MRgRT systems will be used to verify treatment setup,
treatment guidance and online adapted radiotherapy. Some MRgRT systems are not
equipped with lasers in the treatment room and solely depend on MR guidance to
correctly setup a patient. Some systems will require reoptimizing the plan based on MR
images acquired the day of treatment. The overall workflow uncertainty will be evaluated
comprehensively by using IROC-Houston’s MRgRT phantoms as end-to-end test.
MRgRT H&N and thorax phantoms will be essential tools used to credential
institutions participating in NCI sponsored clinical trials. Ultimately, the NCI-sponsored
clinical trials will be used to quantify the benefits of MRgRT systems. The MRgRT
phantoms will contribute to the overall understanding of using on-board MR imagers in
the clinic.
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Chapter 2: Developing and Characterizing MR/CT
visible materials used in QA phantoms for MRgRT systems
A substantial portion of this chapter is written or based on the following publication:
A.Steinmann, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller, D. Followill,
“Developing and characterizing MR/CT visible materials used in QA phantoms for
MRgRT systems,” Medical Physics. Doi: 10.1002/mp.12700. (2018). © John Wiley and
Sons.
The permission for reuse of this material was obtained from John Wiley and Sons.
2.1

ABSTRACT
Purpose: Synthetic tissue equivalent (STE) materials currently used to simulate

tumor and surrounding tissues for IROC-Houston’s anthropomorphic head and thorax
QA phantoms cannot be visualized using magnetic resonance (MR) imaging. The
purpose of this study was to characterize dual MR/CT visible STE materials that can be
used in an end-to-end QA phantom for MR guided radiotherapy (MRgRT) modalities.
Methods: Over 80 materials’ MR, CT, and dosimetric STE properties were
investigated for use in MRgRT QA phantoms. The materials tested included
homogeneous and heterogeneous materials to simulate soft-tissue/tumor and lung tissues.
Materials were scanned on a Siemens’ Magnetom Espree 1.5T using four sequences,
which showed the materials visual contrast between T1 and T2 weighted images. Each
material’s Hounsfield number and electron density data was collected using a GE’s CT
Lightspeed Simulator. Dosimetric properties were examined by constructing a 10 x 10 x
20 cm3 phantom of the selected STE materials that was divided into three sections:
anterior, middle, and posterior. Anterior and posterior pieces were composed of
polystyrene, whereas the middle section was substituted with the selected STE materials.
EBT3 film was inserted into the phantom’s midline and was irradiated using an Elekta’s
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Versa 6 MV beam with a prescription of 6 Gy at 1.5 cm and varying field size of: 10 x
10 cm2, 6 x 6 cm2, and 3 x 3 cm2. Measured film PDD curves were compared to planning
system calculations and conventional STE materials’ percent depth dose (PDD) curves.
Results: The majority of the tested materials showed comparable CT attenuation
properties to their respective organ site; however, most of the tested materials were not
visible on either T1 or T2 weighted MR images. Silicone, hydrocarbon, synthetic gelatin
and liquid PVC plastic-based materials showed good MR image contrast. In-house lung
equivalent materials made with either silicone or hydrocarbon-based materials had HUs
ranging from: -978 to -117 and -667 to -593, respectively. Synthetic gelatin and PVC
plastic-based materials resembled soft tissue/tumor equivalent materials and had HUs of:
-175 to -170 and -29 to 32, respectively.
PDD curves of the selected MR/CT visible materials were comparable to IROCHouston’s conventional phantom STE materials. The smallest field size showed the
largest disagreements, where the average discrepancies between calculated and measured
PDD curves were 1.8% and 5.9% for homogeneous and heterogeneous testing materials,
respectively.
Conclusions: Gelatin, liquid plastic, and hydrocarbon-based materials were
determined as alternative STE substitutes for MRgRT QA phantoms.
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2.2

INTRODUCTION
Advances in radiation oncology have drastically evolved over the past decade.

Among the many changes, one of the most prominent additions is the use of on board
imaging in conjunction with a radiation therapy treatment modality (i.e., cone-beam CT
guided linear accelerator). While the integration of cone-beam CT (CBCT) with a
modern linear accelerator enables patient set-up verification and target localization; this
imaging modality is often limited to interfraction setup verifications

47-49

. Several

research collaborations were initiated several years ago to integrate a magnetic resonance
imager (MR) with either a 60Co unit or a linear accelerator as a new form of image guided
radiation therapy 13; 48. In comparison with CBCT, the integrated MR can provide images
with superior soft tissue contrast, permit real-time imaging, and not cause any additional
radiation dose. The incorporation of a magnetic resonance guided radiation therapy
(MRgRT) modality into the clinic can provide visualization for both intrafractional and
interfractional target motion.
In the United States, there are two MRgRT systems: the Unity developed by
Elekta/Philips (Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands)
which is not yet in clinical use and the ViewRay MRIdian (ViewRay, Oakwood Village,
Ohio) which is in clinical use. The Unity system is equipped with an Elekta 7 MV linear
accelerator that is located in between a Philips’ 1.5 T MR scanner. Due to the active
shielding on the superconducting magnets, a low magnetic field toroid is created, which
enables a linear accelerator to be positioned and operate in between the two magnets with
only a minimal magnetic effect10; 12. In contrast, the MRIdian is a radiation therapy (RT)
treatment machine with three independent 60Co sources located in between a split 0.35T
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superconducting MR imager15. Each of the three 60Co treatment heads are equipped with
a double focused multileaf collimator; thus, permitting the MRIdian unit to have a
comparable penumbra and dose rate as a conventional 6 MV linear accelerator15.
Additionally, ViewRay has developed a linac-based version of the MRIdian system. The
MRIdian Linac, which was FDA approved in February 2017, is an upgraded system that
incorporates a 0.35T superconducting magnetics with a 6 MV linear accelerator.
Both MRgRT systems have the ability to provide real-time imaging and deliver
adaptive RT. Despite the innovation and potential benefits of using a MR unit for
MRgRT treatments, there are challenges that limit a MR-only RT workflow. Two of
these include: 1) the inability to easily determine the patient’s electron density for
treatment planning dose calculations and 2) geometric distortions produced on MR
images

50-54

. Conventionally, the patient’s electron density is indirectly determined

through a bi-linear relationship between the linear attenuation data collected from a CT
and the material’s respectively density. Unlike CT, where images are created from back
projections of photons penetrating the body, MR does not use radiation to produce an
image and solely relies on small fluctuations of the materials’ net magnetic moment. Due
to the inherent differences in the acquisition process of MR and CT, the linear attenuation
data is not collected in MR. Therefore, current MR scanners are unable to indirectly
measure electron density from one scan. Additionally, it is critical to know the exact size
and location of a patient’s anatomy in radiotherapy (RT). MR images commonly
misrepresent actual patient anatomy in space (geometric distortion) due to the inherent
configuration and design of a MR unit55. Nonlinear gradients and heterogeneities in the
static magnetic field primarily contribute to geometric distortions in the image52; 54; 55.
Since geometric distortions and electron densities are limited to the inherent differences
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in the acquisition process between MR and CT, it is critical that current MRgRT
modalities rely on both CT and MR for treatment planning and treatment
verification/treatment adaptation, respectively.
End-to-end QA verifications performed for conventional radiation treatments
have routinely focused on using a CT imager in a radiotherapy modality. However, with
the incorporation of MR in radiotherapy, it is important that end-to-end QA tests expand
to also include MR imagers. Current end-to-end QA phantoms used at the Imaging and
Radiation Oncology Core at Houston (IROC-Houston) QA Center for credentialing
purposes in National Cancer Institute (NCI) funded clinical trials are not MR visible. As
shown in Figure 14, tumor and surrounding tissue in IROC-Houston’s anthropomorphic
thorax phantom are distinguishable in CT images but are not in T1 and T2 weighted MR
images. Dosimetrically the phantoms are accurate, but the plastics used to represent
tumor and surround tissue in IROC-Houston’s phantoms do not yield any MR signal,
which makes these phantoms deficient as end-to-end QA phantoms for MRgRT. Other
researchers have attempted to create dual MR/CT phantoms, but the phantoms are limited
by either: shelf-life storage, require refrigeration or additives to prevent microorganism
growth and therefore were not suitable for shipping to other RT institutions56-58.
The aim of this study was to identify and characterize STE materials that could
be used to develop an anthropomorphic dual MR/CT QA phantom which would require
minimal maintenance and be used to credential RT institutions wishing to use MRgRT
modalities in NCI funded clinical trials.
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Figure 14: Images a-c are used to illustrate the need for a dual CT/MR visible phantom for
MRgRT modalities. This figure displays IROC-Houston’s Anthropomorphic Thorax
phantom imaged in a GE Lightspeed CT simulator (a.) and Siemen’s Magnetom Espree 1.5T
MR scanner (b-c). The phantom’s tumor and lung were constructed out of polystyrene and
compressed cork, respectively. The tumor is located in the phantom’s left lung and is
completely visible on a CT (a.) however, the tumor and surrounding lung tissue are not
visually distinguishable in either a T1-weighted (b.) or T2-weighted (c.) MR image.

2.3
2.3.1

MATERIAL AND METHODS
IROC-Houston’s Traditional QA Phantoms
IROC-Houston’s two anthropomorphic phantoms used most often are the

heterogeneous thorax and homogeneous head and neck (H&N) phantoms. The thorax
and H&N phantoms were previously described in detail by Followill and Molineu,
respectively59; 60. Briefly, the current thorax phantom is a water fillable shell and contains
two lungs made of compressed cork (one with a centrally located target made of nylon).
Other organs at risk represented in IROC-Houston’s thorax phantom include a heart and
spinal cord composed of polystyrene and acrylic, respectively. In IROC-Houston’s H&N
phantom, the primary and secondary targets are constructed out of solid water and are
surrounded by polystyrene. The polystyrene/solid water insert is enclosed into a water
fillable plastic shell, which is shaped as a human head. For both phantoms, the materials
used to simulate the targets and surrounding normal tissues are synthetic, rigid, and
hydrogen deficient. These materials are ideal for traditional QA phantoms since they do
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not require special storage conditions, require minimal maintenance, can easily hold
radiation dosimeters, maintain their shape, are distinguishable using CT, and are
dosimetrically similar to human tissue.

2.3.2

Required Material Properties Used in MRgRT QA Phantoms

To develop an appropriate MRgRT QA phantom, it is vital that the materials used for
this dual modality phantom are: 1) visible on both T1 and T2 weighted MR images, 2)
visible on CT images, and 3) have comparable HUs and dosimetrically simulate tumor
and surrounding tissue. Since IROC-Houston ships their end-to-end QA phantoms to
other institutions, these materials must also satisfy non-dosimetric characteristics. IROCHouston’s MR/CT visible materials must also endure rough shipping conditions, show
longevity without adding preservatives, maintain their physical structure (i.e., high
melting point) and show a relative ease in manipulating the material to form a realistic
tissue shape and hold dosimeters. A wide variety of materials (listed in Table 4) were
tested for their dosimetric, MR and CT compatibility. The materials were first imaged
using a MR and CT scanner. Based on the material’s MR and CT assessment, a decision
was made on what materials to continue with dosimetric testing. Potential materials
examined for a MR/CT QA phantom included: nylon-based, silicon-based, acrylic-based,
and gel-based materials. In addition to commercially purchased materials, some tested
materials were manufactured in-house.

The in-house mixtures incorporated mini

Styrofoam balls with ranging diameters of 2-4mm with either a petroleum or siliconebased material. Combining a based material with Styrofoam balls created a
heterogeneous material that could potentially be used to represent a synthetic lung
equivalent tissue.
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Testing Material

Material Type

HU

Superflab a
SuperStuff a
100% Liquid PVC Plastic b
100% Super Soft PVC Plastic b
90% Liquid PVC Plastic & 10%
Plastic Softener Mix b
100% Plastic Hardener b
75% Plastic Hardener & 25% Plastic
Softener Mix b
75% Super Soft Plastic & 25%
Softener Mix b
75% Liquid PVC Plastic & 25%
Plastic Softener Mix b
Gel #10 c
Gel #20 c
Gel #1 c
Gel #2 c
Gel #3 c
Gel #4 c
Multiwax h
Petroleum Jelly h
91.7% Petroleum Jelly & 8.3%
Styrofoam ball Mix i,‡
95% Petroleum Jelly & 5% Styrofoam
ball Mix i,‡
Dragon Skin 10 g
Dragon Skin 30 g
Dragon Skin FX-Pro g
Eco Flex 00-10 g
EcoFlex 00-30 g
EcoFlex 00-50 g
PlatSil® Gel 00 d
PlatSil® Gel 10 d
PlatSil® Gel 25 d
PlatSil® Gel 00 +H (10:10:10) d,◊
PlatSil® Gel 10 +H (10:10:10) d,◊
PlatSil® Gel 25 +H (10:10:10) d,◊
PlatSil® Gel 25 (20:20:0.5) d,‡
PlatSil® Gel-00/Styrofoam ball Mix
(20g:20g:1g) d,‡
PlatSil® Gel 25 (20:20:1) d,‡
PlatSil® Gel-00/Styrofoam ball Mix
(20g:20g:1.5g) d,‡
PlatSil® Gel 25 (20:20:1.5) d,‡
PlatSil® Gel 25 (20:20:2) d,‡
PlatSil® Gel-00/Styrofoam ball Mix
(10g:10g:1g) d,‡
PlatSil® Gel-00/Styrofoam ball Mix
(40g:40g:1g) d,‡
Nycast ® 6PA- Blue e
Nycast ® 6PA- MoS2 Filled e
Nycast ® 6PA-Orange e
Nycast CP e

Plastic
Plastic
Plastic
Plastic
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Nycast Rx e
Nylon Nyloil e
EP 30 f
EP424T f
PMC ® 121/30 g
PMC ® 744 g
PMC ® 746 g
PMC ® 770 g
PMC ® 790 g
ReoFlex ® 20 g
ReoFlex ® 30 g
Simpact® 85 A g
Simpact® 60 A g
VytalFlex® 10 g
VytalFlex® 20 g
VytalFlex® 30 g

Nylon
Nylon
Epoxy
Epoxy
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane
Urethane

90.9
94.2
72.9
63.0
-10.5
-2.90
-11.0
78.0
66.1
-19.5
-45.0
66.0
71.6
-9.0
-18.3
-27.0

N
N
N
N
Y
N
N
N
N
Y
Y
N
N
N
Y
Y

N
N
N
N
N
N
N
N
N
N
N
N
N
N
N
N

-

a: Radiation Products Design Incorporation, Albertville, Minnesota b: M-F Manufacturing Company, Fort
Worth, Texas c: Clear Ballistics, Fort Smith, Arkansas d: Polytek® Development Corporation, Easton,
Pennsylvania e: Cast Nylons Limited, Willoughby, Ohio f: MasterBond, Hackensack, New Jersey g: SmoothOn Inc., Macungie, Pennsylvania h: Sonneborn, Parsippany, New Jersey ‡:In-house mixture that used %
weight of Styrofoam balls from Steve Spangler Science Styrofoam Beads, Englewood, Colorado.

Table 4: Above is a list of materials tested for a MR/CT visible STE phantom. As displayed in
the second column, testing materials were grouped as: plastic, synthetic gelatin,
hydrocarbon, urethane, epoxy, silicone, and nylon based materials. These material’s HU
were measured from a GE LightSpeed CT Simulator and are displayed in the third column.
The materials were also imaged on a Siemen’s Magnetom Espree 1.5 MR scanner using T1
and T2 weighted sequences. The fourth and fifth columns display whether the materials
could visually be distinguished in T1 and T2 weighted images, respectively. Materials were
visualized on a both T1 and T2 weighted sequences, and also shared reasonable HUs for
either tumor, soft tissue, and lung materials were then dosimetrically tested. The last column
displays whether or not a material was tested dosimetrically. If the material was tested
dosimetrically the final column displays if it was considered STE.

2.3.2.1 MR Imaging
All materials listed in Table 4 were submerged in water and were scanned using
four MR scanning protocols on a Siemen’s Magnetom Espree 1.5T MR scanner (Siemens
Healthcare, Erlangen Germany). Common T1 and T2 MR sequences were chosen based
on an assumption that similar sequences would be equipped in all of MRgRT treatment’s
imaging software. MR scans represented four different MR sequences that were either:
1) currently used in an MRgRT modality (TRUFI) or 2) shared similar sequences (T1-
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weighted and T2-weighted) that were expected to be equipped in all new MRgRT
modalities. All materials were specifically scanned under a TRUFI sequence since
ViewRay exclusively uses this sequence.
Four MR sequences, summarized in Table 5, were used to image the testing
material’s MR properties. The water bath was used as a baseline to assess the material’s
contrast in various MR sequences. A T1-weighted image was obtained from a 3D
gradient echo sequence and used the following parameters: FA= 25°, TR= 9.5 ms, TE=
4.68 ms, ETL= 1, NEX=1. A true fast imaging with steady-state free precession
sequence, commonly referred as a TRUFI sequence, was acquired with the following
parameters: FA= 70°, TR= 4 ms, TE= 2 ms, ETL= 1, NEX=1. Two additional T2weighted images were also obtained for each material. The first T2 weighted image was
a gradient sequence and had parameters of: FA= 120°, TR= 3200 ms, TE= 245 ms, ETL=
109, NEX=2. The second T2-weighted image used a fluid-attenuated inversion recovery
sequence, commonly referred as a FLAIR sequence, and had scanning parameters of:
FA= 120°, TR= 5000 ms, TE= 336 ms, ETL= 109, NEX=2.

Scanning
T1-Weighted
TRUFI
T2-Weighted
FLAIR
Sequence
Gradient
Gradient
FA
25°
70°
120°
120°
TR (ms)
9.5
4
3200
5000
TE (ms)
4.68
2
245
336
ETL
1
1
109
109
NEX
1
1
2
2
Table 5: Four MR scanning parameters were used to visually compare the selected material's
contrast between water. Among the parameters, a T1 weighted and T2 weighted sequence
were scanned based off of the assumption that other MRgRT systems would have the
capability to image basic T1 weighted and T2 weighted protocols. A TRUFI sequence was
scanned to ensure that the materials could be visualized on ViewRay systems. Since FLAIR
sequences are commonly used to enhanced lesions in the clinic, a FLAIR sequence was also
used to compare the selected material’s contrast.
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2.3.2.2 CT Imaging
All of the materials listed in Table 4 were submerged in a water bath and were
scanned using a brain protocol on a GE Lightspeed CT simulator (General Electric
Company, New York, New York). The scanning parameters were: DFOV= 500.0 mm,
120 kVp, 275 mA, and slice thickness= 3mm. The materials’ HU were obtained after
exporting the CT images into Philips IntelliSpace PACS Enterprise (Philips, Amsterdam,
Netherlands) system.
2.3.2.3 Dosimetric properties
A dual MR/CT visible end-to-end QA anthropomorphic phantom used in
radiotherapy must also dosimetrically represent human tissue. Percent depth dose (PDD)
curves were obtained to determine the material’s dosimetric properties on materials that
were MR/CT visible. As shown in Figure 15, a 10 cm x 10 cm x 20 cm rectangular
phantom was constructed to determine the PDD for selected MR/CT visible materials.
The 20 cm long PDD phantom was divided into three sections: anterior, middle, and
posterior, which had lengths of 5.0 cm, 10.0 cm, and 5.0 cm, respectively. The anterior
and posterior sections were composed of polystyrene, whereas the middle section was
substituted with materials that were visible on both CT and MR. Additionally, two
materials commonly used in IROC-Houston’s QA phantoms (compressed cork and
polystyrene) were included in this study to provide controlled PDD curves.
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Figure 15: PDD phantom was used to determine the testing material’s dosimetric properties.
The PDD phantom was divided into three subsections where the anterior and posterior
sections were composed of polystyrene and the middle section was interchanged with testing
materials. Film was placed in the sagittal plane to measure the material’s PDD curve.

The 6 MV beam from an Elekta Versa HD (Elekta, Stockholm, Sweden) was used
to irradiate the PDD phantoms with three different field sizes of: 10 x 10 cm2, 6 x 6 cm2,
3 x 3 cm2. During each irradiation, EBT-3 radiochromic film was inserted into the
midline of the PDD phantom. Additional 5 cm of polystyrene was placed around the PDD
phantom which ensured proper scatter conditions. Within each field size, the PDD
phantom was irradiated three times with a prescribed dose of 600 cGy to dmax (d=1.5 cm).
It was also important to assess how accurate the experimental PDD curves
compared to the treatment planning system (TPS). A treatment plan was created among
the testing materials for each of the three field sizes. Using Pinnacle’s treatment planning
(Philips, Amsterdam, Netherlands), the dose from 0.5 to 17.0 cm was calculated and
normalized to a depth of 1.5 cm using the collapsed cone dose algorithm. After the films
were irradiated, a photoelectron CCD microdensitometer (Photoelectron Corporation,
North Billerica, Massachusetts) was used to capture the optical density of the film at the
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different depths of interest. The intensity of the film was then converted into dose and
the dose at the varying depths were normalized to the dose at 1.5 cm.

2.4
2.4.1

RESULTS
Tested Material’s Properties

2.4.1.1 MR properties
Most plastic, silicone, and gelatin-based materials tested were visible in both T1
and T2 weighted images.

In-house mixtures were mostly visible on all four MR

sequences. Specifically, testing materials that used either Polytek Development
Corporation’s Gel 25 or M-F Manufacturing Company’s 100% Plastic Hardener were
visible on T1-weighted images but were not visible on T2-weighted images. With few
exceptions most nylon, urethane, and epoxy-based materials were not visible on either
T1 or T2 weighed MR sequences. Specifically, Smooth-On’s Reoflex 20, Reoflex 30,
VytalFlex 20, VytalFlex 30, and PMC 121/30 materials were all urethane-based materials
and were only visible on T1-weighted images.
Materials that were heterogeneous and showed a random absence of signal were
more favorable lung materials compared to the homogeneous substitutes since these
materials were better representations of lung tissue. Heterogeneous tested materials were
constructed in-house and were combined with a base material (either Sonneborn’s
petroleum jelly or Polytek Development Corporation’s silicon gels) and different
concentrations of 2-4mm miniature Styrofoam balls. Within the heterogeneous lung
materials, miniature Styrofoam balls represented air pockets with no MR signal while the
surrounding base materials generated MR signal. MR visibility of potential lung41

equivalent materials greatly depended on the Styrofoam ball concentration. As the
concentration of Styrofoam balls increased, the MR visibility greatly decreased since
there was less signal from the surrounding materials. Among the in-house mixtures, the
most visible lung substitute was a combination of 8.3% weight of Styrofoam balls and
91.7% of petroleum jelly (Figure 16).
Contrary to potential lung candidates, homogeneous materials better represented
soft tissue and tumor substitutes. Potential soft tissue and tumor substitutes were not
required to have the same grey-scale contrast as their human flesh counterparts, but these
materials were required to have visible contrast between water and each other. Taking
into account all four MR sequences, three materials (Clear Ballistics’ Gel #20, M-F
Manufacturing Company’s 100% Liquid PVC Plastic, and Radiation Products Design
Incorporation’s Superflab) were shown to have the most visible contrast between water,
each other and other testing materials. Therefore, Gel #20, 100% Liquid PVC Plastic and
Superflab were chosen to be tested further as suitable soft tissue or tumor substitutes
(Figure 16).
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Figure 16: From top to bottom the materials shown are: 1.) compressed cork, 2.) in-house
petroleum/styrofoam mixture (8.3% weight composed of mini Styrofoam balls and 91.7%
weight composed of Sonneborn’s Petroleum jelly), 3.) polystyrene, 4.) Clear Ballistic Gel #20,
5.) M-F Manufacturing 100% liquid PVC plastic, and 6.) Superflab. Four different MR
sequences (a-d) and a CT scan (e) were performed on these materials to visually determine
their contrast between water and IROC-Houston’s conventional materials. The MR
sequences shown in this figure were a (a.) T1-weighted, (b.), TRUFI, (c.) T2-weighted, and
(d.) fluid-attenuated T2-weighted scans. The HU measured from the CT image for
compressed cork, in-house petroleum/styrofoam mixture, polystyrene, Clear Ballistic Gel
#20, Liquid plastic, and Superflab were, respectively, -800, -685, -33, -160, 20 and 51.

2.4.1.2 CT properties
The testing materials’ (listed in Table 4) HU was measured from images acquired
on GE’s Lightspeed CT simulator. In general, homogeneous plastic, nylon, epoxy-based
materials most resembled soft tissue and their HU’s, ranging from, -29 to 65, 82 to 161,
63 to 72, respectively. Urethane based materials showed a larger HU range of -45 to 78.
Gelatin based materials resembled more fatty-like tissues with HU’s ranging from -164
to -175 whereas homogenous silicone materials resembled more contrast-enhanced soft
tissue with HU’s ranging from 185 to 319. In-house mixtures, that incorporated either
silicone or hydrocarbon-based materials, visually and numerically simulated lung-like
materials with HU’s that ranged from, -978 to -117 and -667 to -593, respectively.
Similar to MR, the concentration of the Styrofoam balls directly affect their attenuation
coefficient. Mixtures with greater Styrofoam ball concentrations had more air pockets
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which, enable the synthetic materials to better visually resembled lung tissue and had
lower HU values.
The four selected MR-visible materials were collectively imaged on GE’s
Lightspeed CT simulator and are displayed in Figure 16e. Among the four selected MRvisible materials 100% Liquid PVC Plastic, and Superflab numerically represented soft
tissue with HU of -10.4, and 59.9, respectively. Visually, the 100% Liquid PVC Plastic
and Superflab materials had similar contrast as water, whereas Gel #20, showed a greater
contrast relative to water and had a lower HU value of -170. Clear Ballistics’ Gel #20
could potentially be used as either a fat or a tumor equivalent material since it did have
lower HU value than water. Small fluctuations between mini Styrofoam balls and
surrounding based materials in the heterogeneous mixtures created random signals that
resemble high and low contrast areas. These random signals seen among in-house
heterogeneous mixtures on a MR image were also comparable to random signal seen in
lung tissue on a CT image. The in-house mixture with compositions of 8.3% of
Styrofoam balls and 91.7% of petroleum jelly (which was previously selected as a
potential synthetic lung substitute in MR) numerically resembled synthetic lung tissue
with a HU of -685.

2.4.1.3 Dosimetric properties
The selected MR/CT visible materials (in-house 91.7%/8.3% petroleum
jelly/styrofoam mixture, Clear Ballistic Gel #20, and Liquid PVC Plastic) were further
dosimetrically investigated. Since Superflab is currently used in the clinic as a tissue
equivalent material, it was excluded from dosimetric measurement. Each selected
material was irradiated under three different field sizes, then corresponding PDD curves
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were generated using the data from the TPS and radiochromic film. From a depth of 1.5
cm to 17 cm, the deviations between the film PDD and TPS PDD curves were determined
for 10 x 10 cm2, 6 x 6 cm2, and 3 x 3 cm2 field sizes. The greatest deviation between film
and TPS PDD curves was found for the smallest field size for all materials. At a field
size of 3 x 3 cm2 the maximum deviation was: 12.2% at 17.0 cm for compressed cork,
10.8% at 16.5 cm for the in-house petroleum jelly styrofoam mixture, 7.1% at 16.5 cm
for polystyrene, 4.1% at 12.5 cm for Gel #20, and 4.6% at 17.0 cm for 100% Liquid PVC
Plastic (Table 6). While the greatest deviation between film and TPS PDD were shown
for the 3 x 3 cm2 field size, the average deviation for the 3 x 3 cm2 field size for all of the
materials, was less than 6%. The mean deviation between film PDD and TPS PDD for
the selected materials for the 10 x 10 cm2 and 6 x 6 cm2 field sizes were all less than
1.9%, and 2.8%, respectively. Quantitatively, the mean deviation for a 3 x 3 cm2 field
size the mean deviation for compressed cork, the in-house petroleum jelly styrofoam
mixture, polystyrene, Gel #20, and Liquid PVC Plastics were: 3.8 ± 3.60 cm, 5.9 ± 2.75
cm, 1.9 ± 2.02 cm, 1.5 ± 1.15 cm and 2.0 ± 1.13 cm, respectively. At a field size of 3 x 3
cm2 the maximum deviation was: 12.2% at 17.0 cm for compressed cork, 10.8% at 16.5
cm for, 7.1% at 16.5 cm for polystyrene, 4.1% at 12.5 cm for Gel #20, and 4.6% at 17.0
cm for 100% Liquid PVC Plastic (Table 6).
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10 x 10 cm2
Materials

Max
Deviation
[%]

Depth
[cm]

Compress
Cork

4.3

Petroleum
Styrofoam
Mix

6 x 6 cm2

Mean
Deviation
[%]

Max
Deviation
[%]

Depth
[cm]

8.5

1.9
(± 1.12)

5.1

7.7

15.0

1.9
(± 2.04)

Polystyrene

5.7

17.0

Clear
Ballistic
Gel #20

1.9

M-F
Manufacture
Liquid PVC
Plastic

3.7

3 x 3 cm2

Mean
Deviation
[%]

Max
Deviation
[%]

Depth
[cm]

Mean
Deviation
[%]

15.5

2.0
(± 1.24)

12.2

17.0

3.8
(± 3.60)

7.2

13.5

2.8
(± 2.26)

10.8

16.5

5.9
(± 2.75)

1.8
(± 1.67)

2.5

16.0

1.1
(± 0.59)

7.1

16.5

1.9
(± 2.02)

15.0

0.6
(± 0.46)

3.3

14.5

1.2
(± 0.81)

4.1

12.5

1.5
(± 1.15)

16.5

1.2
(± 1.03)

4.5

11.0

1.7
(± 1.21)

4.6

17.0

2.0
(± 1.13)

Table 6: A measured film PDD curve and a TPS PDD curve were generated for both current
IROC-Houston’s phantom materials and testing materials for a large (10 x 10 cm2), medium
(6 x 6 cm2), and small (3 x 3 cm2) field size. For each material (compressed cork,
petroleum/Styrofoam mixture, polystyrene, Clear Ballistic Gel #20, and M-F manufacture’s
liquid PVC plastic) the maximum deviation between the material’s measured PDD and TPS
PDD and the overall mean deviation between 0.5 cm to 17 cm were recorded.

In addition to quantifying the maximum deviation between the film PDD and TPS
PDD for each of the selected materials, the general shape of the tested material’s PDD
curves were compared with PDD curves of current IROC-Houston’s lung and soft tissue
equivalent materials. The in-house petroleum jelly/styrofoam mixture was compared to
compressed cork, which is commonly used as IROC-Houston’s lung equivalent
materials. Similarly, Gel #20, 100% Liquid PVC Plastic were compared to polystyrene,
which is also commonly used as IROC-Houston’s soft tissue equivalent materials.
Collective PDD data for soft tissue and lung equivalent materials for the smallest (3 x 3
cm2) and largest (10 x 10 cm2) field sizes are shown in Figure 17. Overall, the general
PDD curve for Gel #20, and 100% Liquid PVC Plastic agreed with the polystyrene curve
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and the in-house petroleum/styrofoam mixture was in agreement with the compressed
cork curve.

While modest discrepancies between general curve shapes between

compressed cork and the in-house heterogeneous mixture were seen in all three field
sizes, the 3 x 3 cm2 PDD curve showed a slightly higher deviation around 16 cm, where
the lung-to-tissue interface was located. The PDD phantom’s CT, which was used in the
TPS, was not imaged with film sandwich between the two halves. Therefore, it is
believed that the higher deviation between the film and TPS measure in the smallest field
size was primarily due to the dose build up from the film. Additionally, the
petroleum/styrofoam mixture had a slightly higher physical density than compressed
cork, which translated to having a smaller charge particle disequilibrium than compressed
cork.
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Figure 17: The four graphs are a summary of the PDD curve comparisons between IROCHouston’s current soft tissue and lung equivalent materials and testing materials for a large
(10 x 10 cm2) and small (3 x 3 cm2) field size. The interfaces between the testing materials
and polystyrene of the PDD phantom occur between 5 cm and 15 cm. All graphs show the
current tissue substitute’s film (red) and treatment planning (blue) PDD curves. The testing
materials were then compared to current tissue’s film and TPS PDD curves. The greatest
curve deviation occurs for the lung equivalent material for the small field size.

2.5

DISCUSSION
The materials selected for MRgRT end-to-end QA phantoms for IROC-Houston

were based off of three major criteria: practicality, reliability, and accuracy. Since IROCHouston credentials radiotherapy modalities by regularly shipping end-to-end QA
phantoms to institutions, materials selected for a MR/CT visible phantom needed to share
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practical characteristics that would ensure the phantom’s shape and size remain constant
over time. Materials that do not require specific shipping or storage conditions (i.e., could
be left in room temperature, and insensitive to light) and show relative ease in
constructing abnormal shapes were considered as practical materials. Prior to testing a
material’s imaging and dosimetric properties, the material’s melting point was first
investigated. The material’s melting point was used to determine whether a material
could withstand extreme temperatures during shipment. The highest temperatures a
package may experience for domestic and international shipments are, respectively, 37.1
°C and 45.5 °C61. Therefore, it was important that potential candidates had melting points
greater than 45.5 °C. Specifically, the melting points for: Superflab, in-house petroleum
jelly styrofoam mixture, Gel #20, and Liquid PVC Plastics were: 93.3 °C, 58.0 °C, 92.2
°C, and 121.1 °C, respectively. The material’s selection process was also judged based
off of the material’s reliability. Since IROC-Houston’s QA phantoms are used for many
years, the material’s shape and consistency must remain constant over time (i.e., the
materials must not deteriorate or dehydrate over time). The materials listed in Table 4
were tested for their reliability by sitting in room temperature for 3 months. All materials
except for Gel #4 and SuperStuff showed no forms of degradation. In addition to the
practicality and reliability requirements, the materials selected for a MRgRT phantom
had to be visible in common MR sequences, show comparable HU, and dosimetrically
mimic their respective organ site.
Previously reported MR/CT visible materials in the literature did not meet IROCHouston’s criteria since most of these materials shared short shelf lives and required
refrigeration storage56-58. We tested over 80 materials, which could potentially be used to
manufacture IROC-Houston’s MRgRT anthropomorphic phantoms. Most of the test
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materials shared comparable HU values as human tissue but were not visible on both T1
and T2 weighted MR images. Materials that were classified as either epoxy, urethane, or
nylon based sometimes showed contrast in T1-weighted images, but were consistently
not visible in T2-weighted images. Either Polytek’s silicone-based gels or Sonneborn’s
petroleum jelly were mixed with miniature Styrofoam balls in attempts to create various
lung equivalent materials. Styrofoam balls were used to more realistically resemble a
lung’s heterogeneous appearance as viewed in MR and CT, and to lower the HU value.
As we increased the concentration of Styrofoam balls it created a more realistic lung
attenuation coefficient, but consequently, became less visible in MR images. The inhouse mixture of 8.3% Styrofoam balls and 91.7% petroleum jelly was selected as the
most optimal material for a dual modality since it was a good compromised between MR
image visibility and typical lung attenuation data.
Other promising MR/CT visible materials were Smooth-On’s Dragon Skin 30,
Smooth-On’s EcoFlex 50, and in-house mixtures composed of different concentration of
Polytek’s Gel 00 and miniature styrofoam balls. These materials were further
investigated for their dosimetric properties but are not displayed in Figure 16 since these
materials: 1) had higher physical density than their respective organ sites, and 2) did not
have good dosimetric properties.
The selected testing materials visually showed different contrast among the four
MR scans. However, amongst the scans, TRUFI showed the smallest contrast between
the selected MR visible materials. All materials were imaged using a magnetic field of
1.5T. Using a smaller magnetic field (i.e., 0.35T) would generate a smaller net magnetic
moment, which would consequently lower SNR. Lowering the magnetic field strength
could change the material’s T1 and T2 relaxation times which would consequently
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affecting the MR contrast. In order to predict the contrast in a lower magnetic field, the
material’s T1 and T2 relaxations times would need to be calculated.
The measured PDD curves for the selected materials were comparable with their
predicted PDD curves. The general PDD shape of IROC-Houston’s typical soft tissue
substitute, polystyrene, was most comparable to measured PDD curves of Gel #20, and
100% Liquid PVC Plastic. Similarly, the general PDD curve shape of IROC-Houston’s
conventional lung equivalent material, compress cork, was comparable to the in-house
styrofoam/petroleum jelly mixture’s measured PDD curve. Soft tissue equivalent
materials showed a closer PDD curve agreement than lung equivalent materials. While
all PDDs showed expected curve shapes, small differences were only noted for the
smallest field size (3 x 3 cm2) between the testing materials’ measured and predicted
PDD curves.

2.6

CONCLUSION
It was determined that four testing materials were visible and distinguishable in

both MR and CT and dosimetrically represent human tissue. The in-house 91.7%
petroleum jelly/ 8.3% styrofoam ball mixture resembled lung tissue since its HU was
-685, dosimetrically showed expect lung-equivalent PDD curves, and visually showed
random signal in both modalities. Superflab is currently used in the clinics as a tissue
equivalent bolus, so it was only visually examined. It was determined as a potential
material to use in a MR/CT visible phantom, since Superflab was visible in both imaging
modalities. Lastly, Gel #20, and 100% Liquid PVC Plastic were determined to
dosimetrically represent soft tissue and were easily view in both MR and CT modalities
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and was therefore determined that both Gel #20 and 100% Liquid PVC Plastic are
possible tumor equivalent substitutes for MRgRT end to end QA phantoms.
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Chapter 3: Characterize and validate radiation detectors
under the presence of a magnetic field
A substantial portion of this chapter is written or based on the following publication:
A. Steinmann, D. O’Brien, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller, D. Followill,
“Characterization and validation of TLD and Radiochromic EBT3 film under the presence of
1.5T, 0.35T and 0T magnetic field strengths in MR/CT visible materials,” Medical Physics. [In
review] (2018). © John Wiley and Sons.
The permission for reuse of this material was obtained from John Wiley and Sons.

3.1

ABSTRACT
Purpose: The aim of this study was to characterize and validate

thermoluminescent dosimeters (TLD) and radiochromic EBT3 film inside MR/CT
visible geometric head and lung phantoms in the presence of: 0T, 0.35T and 1.5T
magnetic fields.
Methods: TLD reproducibility studies were examined by irradiating IROCHouston’s TLD acrylic block five times under 0T and 1.5T configurations of Elekta’s
Unity system and three times under 0T and 0.35T configurations of ViewRay’s MRIdian
Cobalt-60 (60Co) system. Both systems were irradiated with an equivalent 10 x 10 cm2
field size, and a prescribed dose of 3 Gy to the maximum depth deposition (dmax).
EBT3 film and TLDs were characterized using two geometrical Magnetic
Resonance (MR) guided Radiation Therapy (MRgRT) head and lung phantoms. Each
geometrical phantom had eight quadrants that combined to create a centrally located
rectangular tumor (3x3x5cm3) surrounded by tissue to form a 15x15x15cm3 cubic
phantom. Liquid PVC plastic and Superflab were used to simulate the tumor and
surrounding tissue in the head phantom, respectively. Synthetic ballistic gel and a
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heterogeneous in-house mixture were used to construct the tumor and surrounding tissue
in the lung phantom, respectively. EBT3 and double-loaded TLDs were used in the
phantoms to compare beam profiles and point dose measurements with and without
magnetic fields. GEANT4 Monte Carlo simulations were performed to validate the
detectors for both Unity 0T/1.5T and MRIdian 0T/0.35T configurations.
Results: Average TLD block measurements which, compared the magnetic field
effects (magnetic field vs. 0T) on the Unity and MRIdian systems, were 0.5% and 0.6%,
respectively. The average ratios between magnetic field effects for the geometric lung
and head phantoms under the Unity system were -0.2% and 1.6% and for the MRIdian
system were 0.2% and -0.3%, respectively. Beam profiles generated with both systems
agreed with Monte Carlo measurements and previous literature findings.
Conclusions: TLDs and EBT3 film dosimeters can be used in MR/CT visible
tissue equivalent phantoms that will experience a magnetic field environment.
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3.2

INTRODUCTION
While magnetic fields from both MRIdian (ViewRay, Oakwood Village, Ohio)

and Unity (Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands)
systems do not directly affect their primary photon beam, their secondary electrons are
influenced by the magnetic field via the Lorentz force62. A magnetic field will influence
the electron’s trajectory and will consequently affect the dose deposited in a medium. In
general, the magnetic field will cause an increase in penumbra, a reduction of buildup
and an asymmetric dose profile shift laterally32; 62. Previous studies from Raaymakers et
al. 2004 used GEANT4 to simulate a homogenous water phantom irradiated with a 6 MV
beam perpendicular to a 0T and a 1.5T magnetic field62. In this study, beam profiles
generated under a 1.5T magnetic field shifted 0.7 mm from the 50% isodose line whereas
beam profiles generated without a magnetic field did not shift62.
Magnetic fields can cause irregular dose deposition in heterogeneous materials
due to the secondary electron’s helical trajectories. At tissue-air interfaces, the electrons
traveling out of the tissue medium into air will curve back into the medium and deposit
additional dose laterally33. This phenomenon, known as the electron return effect (ERE),
is dependent on the magnetic field strength and electron energy32. The ERE in tissue-air
interfaces previously has been shown to increase dose up to 40% along the central axis63.
Irregular electron dose deposition, induced from the presence of a magnetic field, could
potentially compromise the accuracy of radiation detectors typically used in
radiotherapy32;

37

. Therefore, typical radiation dosimeters must be analyzed and

characterized in the presence of a magnetic field prior to being used to measure dose in
the clinic.
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TLD-100s (ThermoFisher Scientific, Waltham, MA, USA) frequently are used
by the Imaging and Radiation Oncology Core Quality Assurance (QA) Center in Houston
(IROC-Houston) to measure the delivered dose in anthropomorphic QA phantoms.
Previous studies have started to characterize TLDs in the presence of a magnetic field6466

. Mathis et al. 2014 studied the effects of powder-form TLDs and radiochromic EBT3

film under the presence and absence of a 1.5T magnetic field when exposed to a range
(200cGy to 600cGy) of radiation dose65. In this study, the TLDs and film irradiated with
and without magnetic fields agreed within a 5% criterion65. However, the Mathis et al.
study irradiated TLDs and film using two different machines (a conventional linear
accelerator and an MR-Linac prototype at UMC-Utrecht). Comparing radiation
measurements on two different systems introduced additional uncertainties such as
fluctuations in machine output. Wen et al. 2015 studied the directional dependence of
single-loaded TLD capsules using IROC-Houston’s output verification acrylic TLD
block66. It was noted that the TLD capsules irradiated parallel to a 1.5T magnetic field
experienced a 2.3% higher output compared to TLD capsules irradiated perpendicular to
a 1.5T magnetic field66. This small difference was most likely due to the air gap within
the single-loaded TLD capsule itself. To the authors’ knowledge, no studies have
characterized double-loaded TLDs (no air gap) perpendicular to a radiation beam.
Double-loaded TLDs have twice the amount of LiF:M,Ti than in single-loaded TLDs,
thus, removing the air spacing that are normally found in single-loaded TLDs.
IROC-Houston’s end-to-end phantoms also use radiochromic EBT3 film
(Ashland Inc., Wayne, NJ, USA) to measure the planar dose distribution near the tumor
and organs at risk. Studies have shown that different radiochromic film prototypes (EBT3
and EBT2) respond differently when irradiated in the presence of a magnetic field67-70.
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The protective polyester layers in EBT2 film change after a magnetic field exposure
causing an under response that varies with dose67; 68. Preliminary studies showed that the
EBT3 film’s dose distribution did not change in a magnetic field likely due to EBT3
having a different protective layer than EBT269-71. EBT3 films preliminarily were studied
in 0.35T and 1.5T magnetic field environments. However, there was not a single
comprehensive study used the same experiment methodology to compare the film’s
response to a magnetic field in both MRIdian and Unity systems. Additionally, these
previous studies only compared the film’s relative signal and were not validated with
Monte Carlo measurements62. To the authors’ knowledge, no complete comprehensive
study has characterized and validated TLDs and EBT3 film under the presence of 0.35T
and 1.5T magnetic fields for MRIdian and Unity systems, respectively.
To develop appropriate MRgRT tissue equivalent end-to-end QA phantoms,
radiation detectors used in these phantoms must be characterized and validated under the
presence of a magnetic field first. Since heterogeneous interferences and density can
contribute to the ERE, dosimeters must be characterized under the same material
conditions for which they were designed. The purpose of this study was to characterize
and validate double-loaded TLDs and radiochromic EBT3 film, used in IROC-Houston’s
phantoms, under the presence and absence of a 0.35T and 1.5T magnetic fields for the
MRgRT systems.

3.3

MATERIAL AND METHODS
TLD’s dose response and reproducibility were characterized first using a simple

homogenous acrylic block. Finally, both detectors were characterized in MRgRT
phantom slabs and validated using Monte Carlo calculations. Both TLD acrylic block
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reproducibility studies and geometrical slab phantom studies were conducted on a
Elekta’s Unity system (Elekta, Crawley, United Kingdom and Philips, Amsterdam,
Netherlands) and a ViewRay’s MRIdian

60

Co system (ViewRay, Oakwood Village,

Ohio).

3.3.1

TLD Acrylic Block Reproducibility Studies
IROC-Houston’s TLD acrylic blocks are used to verify the output for

megavoltage beams and are designed with three small cylindrical holes that perfectly fit
TLD capsules. Once a TLD is inserted into the acrylic block, each TLD capsule’s end
will be surrounded by an air channel. The dose deposition of small tissue-air interfaces
will be affected by a magnetic field due to the secondary electron’s curving back into the
tissue-air interface32;
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. This ERE phenomenon also would occur in the acrylic-air

channels in the acrylic block, consequently, affecting the TLD dose measurement. To
minimize any extra dose being deposited in the acrylic-air interfaces, six tight-fitting
acrylic plugs were inserted into all air passages and double-loaded TLDs were used
instead of single-loaded TLDs. A single acrylic TLD block was reloaded and irradiated
five separate times for two magnetic field configurations (0T and 1.5T) on the Unity
system and three separate times for a 0T and a 0.35T magnetic field configuration on the
MRIdian 60Co system. The setup configurations for both MRgRT systems are shown in
Figure 18. During the Unity system irradiations, the acrylic TLD block was placed above
14.5 cm of solid water (Sun Nuclear, Melbourne, FL) to achieve the 143.5 cm SAD
isocenter and a gantry angle of 0°. Additionally, these blocks were irradiated using a 10
x 10 cm2 field size and were prescribed 300cGy at dmax (1.3cm at 0T and 1.7cm at 1.5T).
During the MRIdian system irradiations, the TLD blocks were placed at 80 SSD, and
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were irradiated using an equivalent 10x10 cm2 field size with a prescription of 300cGy
delivered at dmax (0.5cm).

Figure 18: TLD blocks were irradiated at isocenter on Elekta’s Unity system at 0T and 1.5T
magnetic field strengths (a) and on ViewRay’s MRIdian system at 0T and 0.35T (b).

3.3.2

Geometrical Phantom Studies
Radiochromic EBT3 film and TLDs were characterized using two geometrical

head and lung phantoms slabs. These phantoms were developed using tissue equivalent
and MR/CT visible materials which were described in the Steinmann et al. 2018 study72.
Geometrical phantom slabs were constructed from eight 7.5 x 7.5 x 7.5 cm3 quadrants
that had a rectangular (3.0 x 3.0 x 5.0 cm3) tumor centrally located around surrounded
tissue to form two 15 x 15 x 15 cm3 cubic phantoms (Figure 19). A 3.0 cm thick acrylic
sleeve was placed around the entire cubic phantom to ensure that all eight segments were
secured tightly. Having a tight fit was important since it minimized any air gaps between
the quadrants. The geometrical phantoms were constructed using four different MR/CT
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visible tissue equivalent materials. Clear Ballistic Gel #20 (Clear Ballistic, Fort Smith,
AR, USA) and SuperFlab Bolus (Radiation Products Design Incorporation, Albertville,
MN, USA) were used as tumor and surrounding soft tissue materials for the geometrical
head phantom, respectively. The geometrical lung phantom was constructed using 100%
liquid PVC plastic (M-F Manufacturing Company, Fort Worth, TX, USA) for the tumor
material and an in-house mixture containing 8.3% wt. of Styrofoam balls with diameters
ranging from 2-4 mm (Steve Spangler Science, Englewood, CO, USA) and 91.7% wt. of
petroleum jelly (Sonneborn, Parsippany, NJ, USA) for the surrounding lung tissue. As
shown in Figure 19, EBT3 film was inserted in all three planes and two double-loaded
TLD powder capsules were inserted near the synthetic tumor’s center. The geometrical
phantoms were positioned on the treatment couch so that the TLDs were perpendicular
to the magnetic field.

FILM

TLD

a.

b.

c.

Figure 19: The geometrical lung and head phantoms were constructed out of tissue
equivalent and MR/CT visible materials (figure 19a shows the lung phantom). As shown in
figure 19c, radiochromic films were placed in all three fields and two TLDs were placed
inside the tumor.

Solid water was positioned posteriorly and anteriorly to the geometrical phantom.
Solid water positioned anteriorly was fixed for both MRgRT setups and was used to
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secure the segments together. Solid water positioned posteriorly to the geometrical
phantom allowed the tumor’s center to align with the isocenter. Since the radiation
isocenters were different in the Unity and MRIdian systems, the amount of solid water
varied posteriorly to the phantom. The geometrical phantoms setups for MRIdian and
Unity systems are shown in Figure 20. Under 0T and 1.5T conditions, the geometrical
head and lung phantoms were irradiated five times on the Unity system. The irradiation
parameters on the Unity system were: 10 x 10 cm 2 field size, 131 SAD and prescription
dose of 600cGy delivered at dmax. Under 0T and 0.35T conditions, the two phantoms
were irradiated three times on the MRIdian 60Co system with a prescribed dose of 600cGy
at 0.5 cm depth, an 80 SSD and an equivalent 10x10 cm2 field size. Repeating the
irradiations five times on the Unity system and three times on the MRIdian 60Co system
allowed a total of 20 and 12 TLD readings, respectively. A total of ten axial films were
captured on the Unity system; five axial films were irradiated with 0T and the remaining
five films were irradiated under 1.5T configuration. A total of six axial films were
captured on the MRIdian 60Co system; three were irradiated with 0T and the remaining
three were irradiated with 0.35T. Individual films from each setup were used to create an
average beam profile.
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Figure 20: Head and Lung geometrical slab phantom setups for irradiation using Elekta's
Unity (figure 20a) and ViewRay's MRIdian (figure 20b) systems

TLDs and radiochromic EBT3 film were read and analyzed using the same
standard analysis procedures as IROC-Houston42; 60. TLDs were read by weighing the
amount of lithium fluoride (LiF) powder on a Mettler AT261 DeltaRange (Mettler
Toledo, Greifensee, Switzerland) scale and measuring the light output using a Harshaw
3500 TLD reader (ThermoFisher Scientific, Waltham, MA, USA). TLD readings in the
lung and head configurations were collectively averaged and were compared with and
without a magnetic field for both MRgRT systems. Film was processed by converting
the

optical

density

into

dose

using

IROC-Houston’s

photoelectron

CCD

microdensitometer (Photoelectron Corporation, North Billerica, MA, USA). IROCHouston’s in-house MATLAB software generated dose distributions and profiles.
Measured beam profiles on MRIdian and Unity systems were validated with
Monte Carlo calculations using GEANT4 (v9.6.p04). GEANT4 was chosen to perform
validation measurements since it was a freely available software and previous studies
used GEANT4 to simulate a radiation beam exposed to a magnetic field35; 37; 62; 73-76. The
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GEANT4 application used for this study was developed at MD Anderson Cancer Center
and was described in detail by O’Brien et al. 201635. In short, this application simulated
either a 7 MV or 60Co beam incident to a virtual phantom. The 7 MV beam model was
provided by Elekta and was developed specifically for the Unity system as a point-source
model defined at isocenter (143.5 cm from the target) with a field size of 10x10 cm 2 35;
37

.A
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Co spectrum was used from the International Atomic Energy Agency (IAEA)

phase-space database to simulate a ViewRay configuration. This phase-space data was
based on of Mora et al.’s 1999 60Co beam model with a 2cm source capsule77.
A virtual head and lung phantom was created in GEANT4. The materials in these
virtual phantoms could be defined several ways in GEANT4. Some generic materials
(i.e., water, air) were predefined in GEANT4’s material database while others could be
defined manually if the chemical composition and density were known. The tissue
equivalent MR/CT visible materials used to construct the geometrical slab phantoms
were not available in GEANT4’s material database; so, the chemical composition and
density were reported. The four materials used in the geometrical phantoms were sent to
Intertek Pharmaceutical Services (Whitehouse, NJ, USA) to determine the materials’
carbon, hydrogen, nitrogen, oxygen and chloride content. The Intertek Pharmaceutical
Services used a Perkin-Elmer 2400 elemental analyzer to determine the elemental
composition of carbon, hydrogen, nitrogen and oxygen and a Calorimetric Titration to
determine the chloride content. The results provided from the Intertek Pharmaceutical
Services are shown in Table 7.

63

Tested Material
Synthetic Gel #20
Superflab

Liquid PVC Plastic

Material
Application
H&N
Tumor
Surrounding
H&N Soft
Tissue
Lung Tumor

Carbon
84.7 %

Elemental Composition
Hydrogen Nitrogen Oxygen
15.3%
<0.05%
<0.05%

Chloride
-

68.8%

11.0%

<0.05%

12.4%

7.8%

66.2%

11.9%

<0.05%

12.6%

9.3%

In-house
Surrounding
87.2%
12.8%
0.38%
Petroleum/styrofoam Lung Tissue
mixture
Table 7: The percent elemental composition of the four MR/CT visible tissue equivalent
materials used in the head and lung geometrical slab phantoms.

-

The virtual phantoms had the same geometry as the physical phantoms. The
virtual phantoms were designed with a centrally located rectangular 5.0 x 3.0 x 3.0 cm3
tumor inside a 15 x 15 x 15 cm3 cubic phantom and 5.0 cm of solid water anteriorly above
the phantom. Both head and lung geometrical slab phantoms were simulated with 0T and
1.5T magnetic fields for a 7 MV beam, and 0T and 0.35T magnetic fields for a
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Co

beam. Four beam profiles were generated in each lung and head phantom for both virtual
and physical environments. For each phantom configuration, two beam profiles were
created from a 60Co beam under 0T and 0.35T magnetic field strengths and the other two
beam profiles were created from a 7 MV beam under 0T and 1.5T magnetic field
strengths.

3.4
3.4.1

RESULTS & DUSCUSSION
TLD Block Reproducibility Studies
Each block had three double-loaded TLD capsules aligned perpendicular to the

magnetic field. Three double-loaded TLDs, in a single acrylic block, created six TLD
readings per irradiation. The average measured TLD doses in the presence or absence of
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a magnetic field are listed in Table 8 for Elekta’s Unity and ViewRay’s MRIdian MRgRT
systems. The Unity system’s average TLD doses for 0T and 1.5T magnetic field strengths
were 334.9 cGy (±0.5%) and 333.1 cGy (±1.4%), respectively, whereas the MRIdian
system’s average doses for 0T and 0.35T magnetic field strengths were 273.4 cGy
(±0.9%) and 275.1 cGy (±1.0%), respectively. The average ratio between measurements
with and without magnetic fields of the Unity and MRIdian systems were 0.995 and
1.006, respectively. The standard deviations of the average TLD doses for all conditions
were small (<1.4%) and showed excellent reproducibility in the TLD readings.
A two-sided, unpaired T-test was used to determine whether there was a statistical
significance between TLDs exposed with and without magnetic fields. With a 95%
confidence interval, both ViewRay (p>0.08) and Unity (p> 0.06) p-values were greater
than 0.05, thus suggesting with a 95% confidence, that there was not a statistical
significance between TLDs irradiated with and without magnetic field. Since the p-values
were close to 0.05, a followed up was done with a two one-sided equivalence test (TOST)
to determine whether TLDs irradiated with a magnetic field were statistically equivalent
to TLDs irradiated without a magnetic field. The delta used for the TOST allowed the
differences in means to be within 1%. The TOST test showed p-values <0.05 (Unity:
p<0.04 and MRIdian: p<0.02) on both MRgRT configurations. Therefore, with 95%
confidence, the TOST test indicated that TLDs irradiated with and without magnetic
fields on the same treatment system were statistically equivalent.
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Unity
Acrylic
TLD
Blocks

0.0T

1.5T

[cGy]
334.9

[cGy]
333.1

( ± 0.5% )

(± 1.4%)

n=5

n=5

MRIdian
Ratio
[1.5T/0T]

0.995

0.0T

0.35T

[cGy]
273.1

[cGy]
275.1

(± 0.9%)

(± 1.0%)

n=3

n=3

Ratio
[0.35T/0T]

1.006

Table 8: The acrylic block TLD irradiations for both MRgRT Unity and MRIdian systems in
the presence and absence of the magnetic field. All standard error of means were less than
1.4%. (Note: n corresponds to the number of times the acrylic block was irradiated under a
specific condition.)

With MRgRT systems recently installed in the radiation oncology centers and
recently used in NCI supported clinical trials, future large multi-institutional clinical
studies will be conducted on these systems. IROC-Houston has the responsibility to
ensure that these systems can treat patients in a comparable and accurate manner, which
is accomplished through IROC-Houston’s end-to-end anthropomorphic QA phantoms by
credentialing institutions wishing to participate in NCI sponsored clinical trials.
Institutions’ performances are analyzed by comparing measured TLD and radiochromic
film to expected treatment plans. Double-loaded TLDs are equipped with 22 mg of
powder LiF compared to 11 mg of LiF found in single-loaded TLDs. The extra powder
effectively eliminates any air gaps within the capsules and allows for two reading
measurements. Double-loaded TLDs were used to mitigate any potential ERE effects due
to the absence of any air gaps. Dose measurements with double-loaded TLDs in the
acrylic blocks and geometrical slab phantoms were shown not to be affected by ERE in
both MRgRT systems when comparing doses with and without magnetic fields.
Our results agreed with previous studies, showing that there is not a statistical
difference between TLDs irradiated with and without magnetic fields for both ViewRay
and Unity systems. Furthermore, our studies showed smaller differences in the ratios
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between TLDs irradiated in 0T and 1.5T environments than shown in previous studies.
Specifically, we found TLDs to be within 0.6% compared to a previous study that found
TLDs to be within 5%65. One reason our results had greater agreement was attributed to
the TLD readout process. IROC-Houston has an established TLD readout process that
allows TLDs to be measured within 2.3% certainty (at 1 standard deviation)42. This study
used standardized double-loaded TLD capsules, whereas the previous study selfpackaged LiF and self-measured the TLD dose. If a user had less experience, TLD
uncertainties could be as great as 4.6% (at 1 standard deviation)78. Additionally, the
previous study examined the magnetic effect on TLDs by comparing the TLD response
on two different systems: a conventional 6 MV linear accelerator (B=0 T) and a 6 MV
MR-Linac (B= 1.5T)65. Directly comparing TLDs irradiated with and without magnetic
fields on two different systems will introduce greater uncertainties. This work had the
unique opportunity to irradiate the TLD acrylic blocks and geometrical phantoms with
and without magnetic field using the same machine for both MRIdian and Unity
treatments.
While this work was performed on the same unit, the window of opportunity to
irradiate the phantoms with and with a magnetic field was extremely limited. The magnet
on an MRgRT unit was ramped down rarely and were usually ramped down to perform
upgrades on the system. Due to the time constraints, the phantoms and TLD blocks were
only irradiated three and five times on the MRIdian and Unity MRgRT systems,
respectively, yet the phantoms were irradiated on a single system and had direct
comparisons between irradiations with and without a magnetic field. The output of the
machines, when irradiated with and without magnetic fields, were assumed to have
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negligible fluctuations. The Unity system, based on a series of output measurements, had
less than a 0.7% fluctuation in the output over time35.

3.4.2

Geometrical Slab Phantom Studies
Radiochromic EBT3 film and double-loaded TLDs were irradiated in both the

head and lung geometrical phantoms. TLDs were read in-house using IROC-Houston’s
standard reading procedure. The measured TLD doses for each phantom type, i.e. head
and lung, were averaged and are shown in Table 9 for the two MRgRT systems. The
average Unity system TLD doses for 0T and 1.5T magnetic fields were 491.9 cGy
(±1.5%) and 492.9 cGy (±1.3%) for the geometrical lung phantom and 453.1 cGy
(±0.7%) and 441.6 cGy (±1.6%) for the geometrical head phantom. The average
measured TLDs ratios between without/with magnetic fields in the Unity system
configuration for lung and head phantoms were, respectively 1.002 and 0.984. The ratio
of 0.984 comparing 1.5T dose measurements to those without any magnetic field was
corrected due reconstructing the geometrical head phantom’s quadrants between the 0T
measurements and the 1.5T measurements. After 0T measurements, it was discovered
that the Superflab had interacted with the high-impact polystyrene (HIPS) barrier used to
encapsulate the gel materials it, so, the HIPS was replaced with solid water. After the
1.5T measurements it was realized that the geometrical head phantom’s modified solid
water exterior thickness was thicker than the original HIPS and resulted in a 1.008
correction to the original values. For the MRIdian 60Co system, the average TLD doses
for 0T and 0.35T magnetic field strengths were 296.4 cGy (±1.1%) and 295.7 cGy
(±1.1%) for the geometrical lung phantom and 271.7 cGy (±1.1%) and 272.4 cGy
(±1.2%) for the geometrical head phantom, respectively. The average ratios of measured
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TLD average doses for the MRIdian system comparing with to without magnetic fields
for the lung and head phantoms were 0.998 and 1.003, respectively.
The ratios between TLD irradiated with and without magnetic fields on a single
MRgRT system were all within 1.6%, which is well within IROC-Houston’s 2.3% TLD
uncertainty. The TLD results agreed with previous studies using a thimble ion chamber
(Exradin A1SL) that showed a 1.26% higher dose output in the 1.5T than in a 0T
magnetic field environment79. TLDs agreeing within 1.6% would suggested that the ERE
effect is not affecting double-loaded TLDs dosimetry in either homogenous or
heterogeneous configurations. If the magnetic field influenced the TLD dose, it was
within the TLD’s inherent dose measurement 2.3% uncertainty and could not be
delineated physically from the TLD reading uncertainty42. Therefore, these results would
conclude that double-loaded TLDs were sufficient dosimeters to measure dose in 0.35T
to 1.5T environments.

Miniature
Phantom
Lung
Head

0.0T
[cGy]
491.9

Unity
1.5T
[cGy]
492.9

Ratio
[1.5T/0T]

(± 1.5%)

(± 1.3%)

1.002

453.1

446.1

(±0.7%)

(± 1.6%)

0.0T
[cGy]
296.4

MRIdian
0.35T
[cGy]
295.7

Ratio
[0.35T/0T]

(± 1.1%)

(±1.1%)

0.998

271.7
272.4
0.984*
1.003
(± 1.1%)
(± 1.2%)
Table 9: Geometrical lung and head phantoms measured doses with and without magnetic
field from a total of five and three times irradiations on the Unity and MRIdian systems,
respectively. All standard errors of the means were less than 1.6%. *Corrected by 1.008 for
the increased barrier thickness.

Radiochromic EBT3 films were used to measure beam profiles centrally located
inside the geometrical phantoms. The right/left axial beam profiles were analyzed due to
the ERE affecting the lateral planes in both ViewRay and Elekta systems. The measured
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and simulated beam profiles for the head and lung geometrical phantoms in the presence
and absence of a magnetic field were compared and are shown in Figure 21 and Figure
22 for the Unity and MRIdian systems, respectively. Figure 21b shows a disagreement
in the shoulder region between the two profiles due to an accumulation of petroleum gel
without styrofoam beads that was not simulated in the GEANT4 Monte Carlo. Monaco
treatment planning software was used as a different dose calculation method to validate
the geometrical lung’s 1.5T film measurement. Under all conditions the two curves
(simulated vs. measured) fall within the measurement uncertainty as evidenced by the
error bars. The absolute differences between measured and calculated beam profiles were
compared at the 80%, 50% and 20% dose levels along the edge of each set of profiles.
The differences are shown in Table 10 for the Unity MRgRT system with the exception
of the shoulder region (80% dose level) of the Unity lung phantom comparisons as
explained above. The maximum average difference between the measured and calculated
profiles was less than 2.2 mm.
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Normalized
Dose

Figure 21: Beam profiles comparing GEANT4 Monte Carlo measurements and EBT3 film
for the geometrical lung (a-b) and head (c-d) phantoms that were irradiated on Unity’s 7 MV
beam under 0T(a and c) and 1.5T (b and d) magnetic field strengths. The error bars were
calculated using the standard error of mean.

Lung
Unity B= 0T
DTA [mm]

Head
Unity B= 1.5T
DTA [mm]

Unity B= 0T
DTA [mm]

Unity B= 1.5T
DTA [mm]

80%
1.1 ± 0.7
1.2 ± 0.8
0.9 ± 0.7
50%
0.5 ± 0.3
1.3 ± 0.7
0.3 ± 0.3
0.5 ± 0.4
20%
2.2 ± 1.0
1.2 ± 0.3
1.4 ± 0.5
0.3 ± 0.3
Table 10: Measure distance at 80% and 50% on both left and right side of the beam profiles
were used to calculate absolute differences between measured and simulated beam profiles
on the Unity’s 0T and 1.5T for both head and lung phantoms. Average absolute differences
between both left and right sides of the curves were recorded

Virtual beam profiles were generated by modifying the Monte Carlo code used in
the O’Brien et al. 2016 study35. These modifications included: 1) adding a virtual
geometrical phantom and 2) defining the chemical compositions of the MR/CT visible
tissue equivalent materials used in the geometrical phantoms. The most accessible and
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practical way to define the materials in GEANT4 was to describe their chemical
composition and density. The material safety data sheets and patents of each material
used in the geometrical phantoms gave a general idea of the elements used in each
material. Tests performed by Intertek Pharmaceutical Services measured the percentage
of specific elements thought to be used in each material. It should be noted that there are
uncertainties in estimating the elements in the materials. It was thought that the materials
only had oxygen, nitrogen, hydrogen, carbon and chloride elements, and thus only those
elements were examined. Each elemental composition test added an uncertainty of up to
0.4%. Since only five elements were assessed, there were additional uncertainties as to
other possible elements present in the materials which were not defined in the Monte
Carlo.
a.

a

c.

c
.

.

b.

b
.

d.

d
.

Figure 22: Beam profiles comparing 0T and 0.35T for the geometrical lung (a-b) and head
(c-d) phantoms that were irradiated on MRIdian’s 60Co beam (a and c) and Monte Carlo
generated beam profiles using Geant4 (b and d). The error bars were calculated using the
standard error of mean.
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Normalized
Dose

Lung
Head
Geant4:
Geant4:
Film:
Film:
B= 0T VS
B= 0T VS
B=0T VS
B=0T VS B=0.35T
B=0.35T
B=0.35T DTA
B=0.35T
DTA [mm]
DTA [mm]
[mm]
DTA [mm]
80%
0.4 ± 0.3
0.6 ± 0.3
0.1 ± 0.1
0.5 ± 0.5
50%
0.4 ± 0.2
0.4 ± 0.3
0.2 ± 0.1
0.4 ± 0.2
20%
0.6 ± 0.3
0.4 ± 0.2
Table 11: Measured distance at 80% ,50% and 20% on both left and right sides of the beam
profiles were used to calculate absolute differences between MRIdian’s 0T and 0.35T
configurations for Monte Carlo (Geant4) and measured films. The average differences
between the beam profiles were measured for both lung and head phantoms.

Figure 22 displays measured and generated beam profiles for lung and head
configurations using the MRIdian system. The absolute differences between 0T and
0.35T beam profiles generated on Monte Carlo were compared to the absolute differences
between 0T and 0.35T beam profiles measured on film. The absolute differences were
compared at 80%, 50% and 20% for each profile set. Table 11 displays the average
differences using the MRIdian configuration. The maximum average difference between
0T and 0.35T was 0.6 mm for film and 0.4 mm for Monte Carlo. Under all conditions,
the two curves fall within the measurement uncertainty as evidenced by the shown
standard deviation. Despite the disagreement seen in the penumbra between measured
and Monte Carlo generated beam profiles, both curves showed that low magnetic fields
(i.e., 0.35T) did not shift the beam profiles and showed the same beam profile shape as
0T configurations. This result would suggest, at first order, the 0.35T magnetic field
environment does not influence the dose deposition on the EBT3 film.
The MRIdian system was simulated using an open-source head model, provided
from the International Atomic Energy Agency. This phase-space data simulated a 60Co
capsule with a finite width of 2 cm77. GEANT4 did not accurately simulate a true
MRIdian

60

Co system since the phase space file only accounted for a single multi leaf

73

collimator (MLC) and a common finite source width. The treatment head of an MRIdian
60

Co system has two sets of MLCs that were used to focus the radiation beam to create a

steep penumbra. Having two sets of MLCs allowed a 60Co system to better resemble a
penumbra traditionally seen on a 6 MV linear accelerator. However, the MRIdian

60

Co

system did not have the same penumbra slope as a 6 MV beam. The phase-space file used
to simulate a

60

Co beam had a typical

60

Co treatment head configuration including a

single MCL set. The head configuration could not be altered to better resemble an
MRIdian head configuration due to using a phase-space data with fixed parameters. This
factor created additional uncertainties to the penumbra on the simulated beam profiles of
the MRIdian system since only a single MLC set was simulated. Film validation was
performed by computing the distance to agreement (DTA) between 0T and 0.35 T beam
profiles on film and the DTA between 0T and 0.35T on Monte Carlo simulated beam
profiles.
Two geometrical phantoms were irradiated using EBT3 film on a Unity and
MRIdian system. Monte Carlo generated beam profiles were used to validate EBT3 film
irradiated with and without magnetic fields for Unity and MRIdian MRgRT systems.
Using a 1.5T magnetic field parameter, Monte Carlo accurately resembled film
measurements in a 1.5T environment, thus suggesting that a high field does not affect
EBT3 readings. Higher magnetic fields (i.e., 1.5T) are more likely to have a greater effect
on radiation dosimeters than on low magnetic field environments (i.e., 0.35T), thus
suggesting that EBT3 film also would not affect a lower (i.e. 0.35T) magnetic field
environment. This assumption was proven to be true when comparing the average DTA
between 0T and 0.35T setups for both film and Monte Carlo measurements.
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3.5

CONCLUSION
TLDs irradiated with and without magnetic fields showed high reproducibility in

both MRgRT systems. Both Unity and MRIdian systems showed less than 0.6%
difference in the acrylic block study. Under a homogenous acrylic block setting, the TLD
dose indicates a negligible effect from the presence of a magnetic field in MRgRT
systems with 0.35T and 1.5T magnetic fields. Furthermore, TLD’s and radiochromic
film’s responses are reproducible in MRIdian and Unity systems when using more
complex conditions (i.e., lung and head geometrical slab phantom configurations). The
ratio between TLD doses with and without a magnetic field agreed within 1.6% for
geometrical phantoms irradiated in both MRgRT system. Beam profiles generated from
radiochromic film irradiated in the lung and head geometrical phantoms on the Unity
system agreed very well with the general shape of beam profiles generated from a Monte
Carlo simulation. Beam profiles generated on the MRIdian configurations did not match
beam profiles generated on Monte Carlo due to the limitations of using a phase-space
with fixed parameters that simulated a single MLC set. The beam profiles generated on
Monte Carlo with and without magnetic fields showed similar shifts as beam profiles
measured in the MRIdian system. This study showed that, double-loaded TLDs and
radiochromic EBT3 films can be used in phantoms that will experience a 0.35T to 1.5T
magnetic field.
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Chapter 4: MRgRT Head and Neck QA Phantom:
Design, Construction and Feasibility Study
A substantial portion of this chapter is written or based on the following publication:
A.Steinmann, P Alvarez, H Lee, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller,
D. Followill, “MRgRT Head and Neck Anthropomorphic QA Phantom: Design,
Development, Commissioning and Feasibility Study,” Medical Physics. [In review]
(2018). © John Wiley and Sons.
The permission for reuse of this material was obtained from John Wiley and Sons.

4.1

ABSTRACT

Purpose: The purpose of this paper was to design, manufacture, and evaluate a tissue
equivalent, dual MR/CT visible anthropomorphic Head and Neck (H&N) phantom. This
phantom was specially designed as an end-to-end quality assurance (QA) tool for
magnetic resonance (MR) guided radiotherapy (MRgRT) systems participating in NCIsponsored clinical trials.

Method: The MRgRT H&N phantom was constructed using a water-fillable acrylic shell
and a custom insert that mimics an organ at risk (OAR) and target structures. The insert
consists of a primary and secondary PTV manufactured of a synthetic clear ballistic gel,
an acrylic OAR and surrounding tissue fabricated using melted Superflab. Radiochromic
EBT3 film and TLDs were used to measure the dose distribution and absolute dose,
respectively.
The phantom was commissioned by conducting an end-to-end test that included:
imaging on a GE Lightspeed CT simulator, planning on Monaco treatment planning
software (TPS), verifying treatment setup with MR and irradiating on Elekta’s 1.5T Unity
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MR linac system. The phantom was irradiated three times using the same plan to
determine reproducibility. Three institutions, equipped with either ViewRay MRIdian
60

Co or ViewRay MRIdian Linac, were used to conduct a feasibility study by performing

independent end-to-end studies. TLDs were evaluated in both commissioning and
feasibility studies by comparing ratios of measured TLD to reported TPS calculated
values. Radiochromic film was used to compare measured planar dose distributions to
expected TPS distribution. Film was evaluated by using an in-house gamma analysis
software to measure the discrepancies between film and treatment planning software
(TPS).
Results: Commissioning of the MRgRT H&N phantom on the Unity system resulted in
reproducible TLD doses (SD < 1.5%). The measured TLD to calculated dose ratios for
the Unity system ranged from 0.94 to 0.98. The Viewray dose result comparisons had a
larger range (1.03-0.94) but these depended on the TPS dose calculations from each site.
Using a 7%/4mm (85% pixels passing) gamma analysis, Viewray institutions had
average axial and sagittal passing rates of 97.3% and 96.2% and the unity system had
average passing rates of 97.8% and 89.7%, respectively. All of the results were within
IROC’s 7%/4mm criterion.
Conclusions: An MRgRT H&N tissue equivalent and visible on both CT and MR was
developed. There was no difference in the results noted between Unity, MRIdian Linac
and MRIdian 60Co systems. The MRgRT HN phantom can be used as a credentialing tool
for NCI-clinical trials using MRgRT systems.
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4.2

INTRODUCTION
New radiotherapy devices, referred to as MRgRT systems, integrate an MR

imager with either a linear accelerator or radioactive

60

Co source. Globally, there are

presently four different MRgRT prototypes used in the clinic. These include: the MRgRT
suite (Varian, Palo Alto, California, USA and Siemens, Erlangen, Germany), the Unity
(Elekta, Crawley, United Kingdom and Philips, Amsterdam, Netherlands), the MRIdian
60

Co (ViewRay, Oakwood Village, Ohio), and the MRIdian Linac (ViewRay, Oakwood

Village, Ohio) 10-13. In short, the MRgRT suite is a 1.5T MR-on-rails system that moves
an MR unit into a linear accelerator vault to acquire images. The Unity system is
equipped with a 7 MV beam mounted to a slip-ring gantry located above a modified 1.5T
magnet. The MRIdian and MRIdian Linac systems are equipped with three 60Co sources
and a single 6 MV linear accelerator, respectively, that are centrally located within a split
0.35T magnet. Clinics within the United States either have the MRIdian

60

Co, the

MRIdian Linac, or the Unity system.
Technologies used in an MRgRT system, compared to current image guided
systems, have the potential to revolutionize radiotherapy. Unlike conventional KV or MV
image guided systems, MRgRT systems offer superior soft tissue delineation while not
subjecting the patient to a dose of radiation. The ability to visualize the gross tumor
volume (GTV) could further reduce margins, thereby, reducing normal tissue toxicity
and increasing local control. Acquiring MR images can be done more frequently since
they would not contribute to additional dose. MRgRT systems can monitor treatment
effectiveness since their near diagnostic-quality MR images could delineate between soft
tissue and would be captured before every treatment. Advance radiotherapy techniques
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can be enhanced with an MRgRT system by permitting real-time gating, target tracking
and online adapted radiotherapy80; 81. These techniques would revolutionize radiation
therapy since treatment would be based on the actual disease location at the given time
radiation was delivered.
The safety and usefulness of MRgRT systems are still being investigated. The
National Institutes of Health (NIH) has sponsored several short-term clinical trials that
preliminarily address safety issues in acquiring daily MR images (NCT02973828) and
delivering radiation using MRgRT systems (NCT03284619). Additionally, NIHsponsored clinical trials (NCT03048760, NCT01999062) have begun to investigate how
new MRgRT workflows (i.e., online adapted radiotherapy) and advanced treatment
techniques (i.e., auto-contouring, MR gating) would affect the clinic. NIH has also
sponsored

several

short-term

pilot

studies

(NCT02264886,

NCT02683200,

NCT02701712, NCT02264886) to investigate the effectiveness of using an MRgRT
system for various anatomical locations. While these pilot studies can preliminarily
determine regions that would likely benefit from MRgRT, more extensive multiinstitutional clinical trials will be needed in the future to thoroughly evaluate clinical
outcomes (i.e., local control, survival rates) for a given disease site. A proposed clinical
trial could examine the correlation between local control rates and MR image guidance
on an MRgRT system82. Head and neck (H&N) region tumors would be ideal for this
proposed clinical trial since CT images lack soft tissue delineation83.
In order for radiotherapy centers to participate in large multi-institutional studies,
the National Cancer Institute (NCI) requires each participating institution to be a part of
the Imaging and Radiation Oncology Core (IROC) QA program which includes
credentialing for advanced technologies. The Imaging and Radiation Oncology Core
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quality assurance (QA) center in Houston (IROC-Houston) has been funded by the NCI
since 1968 to ensure all institutions participating in National Clinical Trial Networks
(NCTN) can accurately and consistently deliver radiation doses to trial patients such as
from intensity modulated radiotherapy (IMRT) treatments. IROC-Houston has
developed various on-site and off-site auditing tools to assure quality is maintained
throughout participating institutions. Among such QA tools, IROC-Houston ships offsite anthropomorphic phantoms to credential NCTN trial participants using advanced
technology treatment modalities84. During the credentialing process, the phantom will
undergo the same treatment workflow as a patient would and an end-to-end QA
examination is performed to assess the institution’s ability to deliver the treatment plan.
IROC-Houston has a collection of site-specific anthropomorphic phantoms.
These anatomical regions include: H&N, pelvis, brain, thorax, spine and liver. The H&N
phantom is IROC-Houston’s oldest and most common phantom used in the credentialing
process. This custom phantom is constructed using a solid high impact polystyrene
(HIPS) slab that is fitted into an anthropomorphic shaped human head. The custom insert
contains an acrylic spinal cord, and two (primary and secondary) PTVs manufactured
using solid water which are dosimetrically monitored with radiochromic film and
thermoluminescent detectors (TLD)60. The spinal cord is adjacent to the primary PTV
which requires each institution to create an IMRT plan with a steep dose gradient.
Integrating an MR imager within a radiotherapy system will inherently transform
how treatment plans and deliveries are performed. In order to account for an MRgRT
workflow, comprehensive end-to-end phantoms must be CT and MR compatible.
Conventional IROC-Houston phantoms, designed for CT-only workflows, are not suited
for MR workflow72. The aim of this study was to design, manufacture, and evaluate a
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tissue equivalent MR/CT visible anthropomorphic H&N phantom, that met IROCHouston’s phantom requirements and could be used as a QA tool to credential MRgRT
systems participating in NCI-sponsored NCTN clinical trials.
4.3

MATERIAL AND METHODS
The MRgRT H&N phantom was designed to meet IROC-Houston’s

radiotherapy, diagnostic and practicality criteria. Materials used in the MRgRT H&N
phantom were carefully selected based on findings in the Steinmann et al. 2018 study72.
To meet radiotherapy and diagnostic requirements, the entire phantom was designed to
dosimetrically represent human tissues (i.e., spinal cord, soft tissue) by using materials
that were dosimetrically tissue equivalent and visible on MR and CT imagers. To meet
practicality criteria, materials were carefully selected so that they required minimal
maintenance, did not morph over time, did not require preservatives, and had high
melting points to withstand any harsh shipping conditions. Once the H&N insert was
constructed, the phantom was reproduced on a 1.5T Unity system and then sent out to
three institutions to conduct a miniature end-to-end feasibility study.

4.3.1

Phantom Design
The MRgRT H&N phantom consisted of a water-fillable acrylic shell (The

Phantom Laboratory, Salem, New York, USA) and a custom designed H&N insert.
Externally the hollow acrylic shell was morphed to resemble a human head, but internally
consisted of a rectangular concavity that tightly held a MR/CT compatible insert. The
hollow anthropomorphic MRgRT H&N phantom next to its 7.5 cm x 10.5 cm x 13 cm
custom insert is seen in Figure 23. The custom H&N insert was designed based on a
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Radiation Therapy Oncology Group (RTOG) oropharyngeal protocol (H-0022) which
consisted of two PTVs (primary and secondary) and an OAR60.

Figure 23: The MRgRT H&N Phantom. The phantom consists of a water-fillable
anthropomorphic shell and a MR/CT compatible insert.

Figure 24 displays a CT axial view of the H&N insert. Internally, the insert
consists of: 1) a moon-shaped cylindrical primary PTV, 2) a cylindrical secondary PTV
and 3) a cylindrical spinal cord that simulated an OAR. The primary PTV is adjacent to
the OAR and the secondary PTV is located at a distance. Inferior and superior pieces of
the two-part insert were secured together from two high impacted polystyrene (HIPS)
plastic screws. The MRgRT H&N insert used radiochromic EBT3 film and doubleloaded TLDs as portable dosimeters. A total of three radiochromic films were placed into
the insert to capture axial and sagittal planes. A sagittal film was placed in between the
primary PTV and OAR for each superior and inferior piece and an axial film was inserted
in between the two pieces. Radiochromic films were pinpricked on the outer parameters
to allow for film registration. At the insert’s center, eight double-loaded TLD capsules
were placed into the insert. Half of the TLDs were inserted into the inferior portion and,
the other half were inserted in the same position on the superior piece.
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Figure 24: A CT image of the MRgRT H&N insert.

Clear Ballistic Gel #20 (Clear Ballistics, Fort Smith, Arkansas, USA) was used
to create the PTV structures. The primary and secondary PTV had dimensions of 5.0 cm
in length and had diameters of 4.0 cm and 2.0 cm, respectively. The primary and
secondary PTV held a total of four and two TLDs, respectively. The primary PTV had
TLDs located anteriorly and posteriorly from the center whereas TLDs were held in the
center of the secondary PTV. The OAR was constructed using acrylic (Professional
Plastics, Fullerton, California, USA) which extended 13 cm in length and was 1 cm in
diameter. The OAR held a total of two TLDs. Each TLD was located in the center of the
spinal cord structure in each insert piece. Table 12 summarizes the materials used in each
structure as well as the dimension and total TLDs used. All structures were surrounded
by melted Superflab which was encapsulated in solid water to create a rigid rectangular
structure. Both Superflab and Clear Ballistic Gel #20 were melted at, respectively,
121.1°C and 148.9°C then poured into a solid water mold. The molds were moved to a
vacuum chamber until the melted materials had solidified at room temperature.
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Structure

Material

Diameter
(cm)

Length
(cm)

Primary PTV
Secondary
PTV
OAR

Clear Ballistic Gel #20a
Clear Ballistic Gel #20a

4
2

5
5

Total
TLDs
Used*
4
2

Acrylicb

1

13

2

a: Clear Ballistics, Fort Smith, Arkansas, USA, b: Professional Plastics, Fullerton, California, USA,

Table 12: The materials used to manufacture a MRgRT H&N insert, dimensions of each and
total number of TLD used in each structure (*half of the TLDs were inserted into the inferior
part and the other half inserted into the superior part of the MRgRT H&N insert).

4.3.2

Phantom Imaging
The MRgRT H&N phantom was imaged on a CT simulator, MRIdian 60Co, and

Unity system. The phantom was first scanned using a brain protocol on a GE Lightspeed
CT simulator (General Electric Company, New York, New York, USA) with scanning
parameters of: DFOV= 500.0 mm, 120 kVp, 275 mA, and slice thickness=3mm.
ViewRay’s 0.35T MRIdian

60

Co system captured a single MR image of the MRgRT

H&N phantom using a TrueFISP (true fast imaging with steady-state free precession)
sequence with scanning parameters of: FA=60°, TR=3.33 ms, TE=1.43 ms, NEX=1. A
T1-weighted image was produced from Elekta’s 1.5T Unity system and had scanning
parameters of: FA=8°, TR=8.0 ms, TE=3.6 ms, ETL=136, NEX=1. Table 13 summarizes
the MR scanning parameters on both the MRIdian and Unity systems.
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Parameters

MRIdian

Unity

MR Scanning
Sequence

True Fast Imaging with
T1-Weighted
Steady-state free
Gradient
Precession (TrueFISP)*
FA
60°
8°
TR (ms)
3.33
8.0
TE (ms)
1.43
3.6
ETL
136
NEX
1
1
Table 13: MR images were captured on both MRIdian and Unity systems. The ViewRay
system acquired a TRUFI image and the Unity system acquired both T1- weighted and T2weighted image. * TRUFI and TrueFISP are the same sequence, but under different
manufactures have different names.

4.3.3

Dose Prescription
The prescription dose was based on the dosimetric requirements set for IROC-

Houston’s conventional H&N phantom. The dosimetric criteria is illustrated in Table 14.
The primary and secondary PTV prescriptions required at least 95% coverage of 6.6 Gy
and 5.4 Gy, respectively. Less than 93% of the prescribed dose, for both PTV sites,
received less than 1% of the PTV. The OAR was restricted to receive a maximum dose
of 4.5 Gy and the normal tissue structure was restricted to receive less than 110% (i.e.,
7.3 Gy) of the prescribed dose.
MRgRT H&N
Structure
Primary PTV
Secondary PTV
OAR
Normal Tissue

Dose Prescription
D95 ≥ 6.6 Gy
D99 ≥ 6.1 Gy
D95 ≥ 5.4 Gy
D99 ≥ 5.0 Gy
DMax < 4.5 Gy
DMax ≤ 7.3 Gy

Table 14: During both reproducibility and feasibility studies, treatment plans were based on
the same dose constraints.
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4.3.4

Treatment Delivery
Reproducibility and feasibility studies were conducted on the MRgRT H&N

phantom. During the reproducibility study, the MRgRT H&N phantom was irradiated
three times on a single Unity system and then sent out to three other MRgRT sites to
conduct a multi-institutional feasibility study. During this miniature feasibility study the
phantom was irradiated using two different MRIdian 60Co systems and irradiated once
on an MRIdian Linac system. The MRgRT H&N phantom was evaluated based on an
end-to-end test for both reproducibility and feasibility studies using the TLD and EBT3
radiation dosimeters.
TLDs were read in-house using the same method as IROC-Houston’s off-site
auditing program42. Double-loaded TLDs (ThermoFisher Scientific, Waltham,
Massachusetts, USA) were used as an absolute dosimeter and were read two weeks from
irradiation date to account for fading. The exact amount of lithium fluoride power inside
a double-loaded TLD capsule was weighed using a Mettler AT261 DeltaRange (Mettler
Toledo, Greifensee, Switzerland) scale and light output was measured using the Harshaw
M3500 TLD reader (ThermoFisher Scientific, Waltham, Massachusetts, USA). The
optical density from the irradiated film was read using a photoelectron CCD
microdensitometer (Photoelectron Corporation, North Billerica, Massachusetts, USA).
The measured intensity read on the CCD microdensitometer was converted to dose and
was post processed using an in-house MATLAB software (The MathWorks, Inc., Natick,
Massachusetts, USA).
Treatment delivery was compared to the expected TPS and was analyzed by two
methods. These methods included: 1) comparing the reported to measured dose for each
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TLD location, 2) performing gamma analysis on axial and sagittal films and generating
dose profiles for each orientation.

4.3.4.1 Reproducibility Study
The phantom was filled with water and imaged on a GE Lightspeed CT simulator
using a brain protocol with parameters of: DFOV=500.0 mm, 120 kVp, 275 mA, and
slice thickness=3mm. The CT image was transferred to Monaco TPS (Elekta, Crawley,
United Kingdom) where TLDs, OAR, and PTVs were contoured and an IMRT plan
created. The IMRT treatment plan used nine gantry angles and used IMRT constraints
similar to Tonigan’s thesis using a median complexity treatment plan85.
The MRgRT H&N phantom was positioned on the Unity system’s couch and a
uniform foam coil was placed above the phantom. Figure 25 displays the treatment setup
used for the reproducibility study. Once the phantom was positioned on the couch, the
phantom was moved into the gantry. During each irradiation the phantom captured a T1weighted MR image (with scanning parameters of: FA=8°, TR=8.0 ms, TE=3.6 ms,
ETL=136, NEX=1). The MR image was fused to the CT image using Monaco’s
automatic image fusion tool. The fused image data set was used to re-optimize the dose
distribution based on the phantom’s current position. The adjusted plan was accepted and
was used to treat the MRgRT H&N phantom. The maximum, minimum and mean dose
were recorded on all TLD locations. For each irradiation, the treatment took around 35
minutes and reloading the phantom with new detectors took around 15 minutes. The
MRgRT H&N treatment plan used to compare the treatment plan to the measured dose
was exported from a universal memory thumb drive.
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Figure 25: The MRgRT H&N setup at MD Anderson’s Unity System. The MRgRT H&N
phantom was secured in place with blue tape and a white foam coil was fastened above the
phantom. The coil was used to capture an MR image and remained on during the
irradiation. It should be noted that the coil was lowered close to the phantom’s surface but
did not directly contact the phantom.

4.3.4.2 Feasibility Study
The MRgRT H&N phantom was used to conduct a multi-institutional
feasibility study. During this feasibility study, the phantom was irradiated on
either an MRIdian 60Co or an MRIdian Linac system. Each institution received
detailed instructions which helped to create uniformity between the participating
institutions. These instructions required the institutions to: 1) prepare the phantom
for imaging and treatment (i.e., fill the hollow phantom with tap water and place
the insert into the phantom), 2) capture a CT simulated image, 3) design an IMRT
treatment plan, 4) verify treatment setup by capturing an on-board MR image and
5) deliver the expected IMRT treatment plan. Each institution was also instructed
to contour the TLD capsules and record the TLD’s expected minimum, maximum
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and mean doses. The digital treatment plan data was sent to IROC-Houston, where the
institution’s treatment delivery was evaluated.
4.4
4.4.1

RESULTS
Phantom Imaging
As shown in Figure 26, the MRgRT H&N phantom was imaged using a GE CT

simulator, Unity and MRIdian MRgRT system. All three images in Figure 26 clearly
display distinguishable internal structures. This ability to see contrast between the disease
site and surrounding tissue allows institutions to real-time visualize the phantom during
treatment. The insert’s rigid exterior and OAR are made of solid water and acrylic,
respectively. These materials lack hydrogen content and appear black on the MR image.
The OAR is visualized through the contrast between the absences of signal surrounded
by MR-visible surrounding tissue. In comparison to the MRIdian 60Co system, the Unity
system captures a higher spatial resolution image. MRgRT systems show different
contrasts within the insert. These variations in contrast and spatial resolution are
attributed to the different MR scanning sequences and magnetic fields, respectively. A
T1-weighted imaging sequence was applied to the 1.5T Unity system whereas a
TrueFISP sequence was applied to the 0.35T MRIdian system. The MR image from the
Unity system captures greater susceptibility artifacts compared to the MRIdian image.
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Figure 26: The MRgRT H&N phantom was filled with water and scanned on: (a) GE CT
simulator, (b) Unity system’s 1.5T MRI with a T1 sequence and (c) ViewRay’s MRIdian Co60 0.35T system with a TRUFI sequence. All images clearly show the OAR, primary and
secondary PTV.

4.4.2

Treatment Delivery
Measured TLD readings were compared to the TPS. Ratios between measured

TLD dose to reported dose are shown in
Table 15 and
Table 16 for the commissioning and feasibility study, respectively. TLDs that fall

within 7% (i.e. 0.93 to 1.07) of the reported dose were considered to be within IROC’s
acceptance criteria. For the commissioning study, the average ratio between measured
and reported values for the primary PTV’s superior anterior, inferior anterior, superior
posterior, and inferior posterior TLD locations were: 0.98, 0.96, 0.94, 0.96 and for the
secondary PTV’s superior and inferior were: 0.96 and 0.96, respectively. The first row
in Table 15 and Table 16 displays the average results in the reproducibility study. The
average ratios between measured TLD and reported doses in the feasibility study were:
1.00, 0.99, 0.98, and 0.99 for the primary PTV’s superior anterior, inferior anterior,
superior posterior and inferior posterior locations, respectively. For both studies, the
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ratios between measured TLD readings to treatment planning readings were all within
IROC’s acceptable criteria region.

Reproducibility Test
TLD Location
PTV Sup. Anterior
PTV Inf. Anterior
PTV Sup. Posterior
PTV Inf. Posterior
Secondary PTV: Sup.
Secondary PTV: Inf.

Unity 1-a

Unity 1-b

Unity 1-c

0.97
0.97
0.94
0.94
0.97
0.96

0.98
0.95
0.94
0.95
0.95
0.95

0.98
0.96
0.94
0.94
0.96
0.96

Average
0.98
0.96
0.94
0.95
0.96
0.96

Coefficient
of variance
0.7%
1.5%
0.4%
0.9%
1.1%
0.4%

Table 15: Reproducibility results of four TLD positions in the Primary PTV. The left column
represents TLD locations for the doses calculated from Monaco’s treatment planning
software. The middle three columns represent the average TLD measured for each location.
The average ratios between measured and calculated dose and the coefficient of variance are
displayed in the right column. The TLD measurements were all within 6% of the reported
TLD dose.

Institution

Energy

Superior
Anterior

Inferior
Anterior

Superior
Posterior

Inferior
Posterior

Unity 1

7 MV

0.98

0.96

0.94

0.95

ViewRay 2

6 MV

1.01

1.01

1.02

1

ViewRay 3

Co-60

1.03

1.03

1.02

1.01

ViewRay 4
Average

Co-60
--

0.98
1.00

0.97
0.99

0.95
0.98

0.99
0.99

Table 16: Feasibility study results for four TLD positions in the primary PTV. Results are the
ratio between measured TLD dose and reported dose from the treatment planning software.

Axial and sagittal films were evaluated using a gamma analysis86. Films were
said to pass if more than 85% of the pixels passed a 7%/4mm criterion. Table 17 and
Table 18 display the percentage of pixels passing the gamma criterion for axial and
sagittal film planes in the reproducibility and feasibility study, respectively. The
commissioning study’s three irradiations had individual passing rates of 96.4%, 98.1%,
and 99.1% for axial films and 89.9%, 89.9% and 89.2% for sagittal films. The average
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percent of pixels passing in the reproducibility study were 97.8% and 89.7% for axial
and sagittal film planes, respectively. For the three feasibility study irradiations on the
MRIdian units, the axial film had individual passing rates of: 97.8%, 97.6%, and 96.7%,
and for the sagittal films had respectively passing rates of: 89.7%, 95.7%, and 95.6%. On
the feasibility study, all axial and sagittal films passed IROC’s gamma criteria with an
average pixel passing of 97.6% and 92.3%, respectively. During the gamma analysis
three dose profiles were generated in anterior-posterior, left-right, and superior-inferior
orientation. The typical dose profiles generated from these studies are shown in Figure
27. From a qualitative perspective, film dose profiles and calculated dose profiles were
in excellent agreement with all studies.

Institution
Unity 1-a
Unity 1-b
Unity 1-c
Average

% Pixel Passing
[±7%/4mm]
Axial Sagittal
96.4%
89.9%
98.1%
89.9%
99.1%
89.2%
97.8%
89.7%

Table 17: The MRgRT H&N phantom was irradiated three times on a 1.5T Unity MR Linac
system. Axial and sagittal planes were evaluated based on 7%/4mm gamma criteria.

Institution
Unity 1
ViewRay 2
ViewRay 3
ViewRay 4*
Average

Energy
7 MV
6 MV
Co-60
Co-60
-

% Pixel Passing
[±7%/4mm]
Axial
97.8%
97.9%
96.7%
97.6%

Sagittal
89.7%
95.7%
96.6%
96.2%

Table 18: Five different MRgRT systems treatments were evaluated based on the 7% dose
and 4mm distance to agreement gamma criteria for both axial and sagittal planes. This table
displays the percentage of pixels passing the gamma criteria. *Data unavailable from
institution for analysis.
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a.

b.

c.

Figure 27: Dose profiles generated in the (a) anterior-posterior, (b) left-right, and (c)
superior-inferior direction. These graphs compare dose profiles generated on film to those
generated from the treatment planning. These graphs were generated from institution 3, but
resemble the typical dose profiles generated from both feasibility and commissioning studies.
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4.5

DISCUSSION
The MRgRT H&N phantom was designed as a tool to credential institutions

wishing to use an MRgRT system to participate in NCI-sponsored clinical trials. IROCHouston’s conventional phantoms were originally designed for CT-only workflow and
constructed of solid materials that were tissue equivalent and visible on CT but were not
visible on MR72. The lack of MR signal in IROC-Houston’s traditional H&N phantom
created a solid black MR image and caused internal structures to be indistinguishable. In
order to use an H&N phantom in all aspects of the MRgRT treatment workflow, it was
critical that the phantom be tissue equivalent and visible in both CT and MR. Having a
multi-modality phantom would truly simulate an MRgRT end-to-end workflow.
Therefore, IROC-Houston’s conventional H&N phantom was an insufficient end-to-end
tool for MRgRT systems since it was not MR visible.
Several studies have attempted to manufacture phantoms that are MR and CT
compatible, but these do not fit IROC-Houston’s requirements. These requirements
include: 1) materials must be dosimetric equivalent to tissue, 2) materials must be MR/CT
visible, 3) portable radiation dosimeters are easy to install into the insert, 4) phantom
insert must be durable, and 5) the phantom requires minimal maintenance (i.e., can be
stored at room temperature). Some studies have created H&N phantoms using materials
that either had short shelf-lives, required additional additives to prevent micro-organism
infestation or required special storage conditions (i.e., refrigerators)57; 87. Some studies
attempted to construct a dual MR/CT H&N phantom by adding MR visible markers to
phantoms that are traditionally used in CT-only workflow88; 89. Other MR/CT compatible
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H&N phantoms are simplistic and were designed to address different challenges in MRonly workflows90. These phantoms were not designed to perform end-to-end tests, but
instead they were designed to quantify MR distortion and study the ability to create
synthetic electron density from a MR image. Therefore, there is not an end-to-end
MRgRT H&N phantom which supports portable dosimeters and have complex multicontrast internal structures.
The MRgRT H&N insert was constructed from gel-based materials. Gel-based
materials, compared to solid materials, were more difficult to manufacture and required
extra construction time since these materials could not precisely be sculpted into a
complex internal structure. The construction process to create precise structures using
gel-based materials included: 1) melting Superflab (121.1 °C) and Clear Ballistic Gel #20
(148.9 °C), 2) pouring melted materials into custom made molds and 3) storing materials
in an air-tight vacuum until solidified. The vacuum chamber was used to eliminate air
bubbles created during the pouring process and the molds were used to create precise and
reproducible structures. To increase rigidity and to sustain shape during rough shipping
conditions, solid water was used to encapsulate internal structures and to create an
exterior insert shell.
IROC-Houston’s conventional phantoms are also equipped with several film pin
prick registration locations. The purpose of these small pinpricked areas is to identify the
film’s location relative to the phantom’s location. Film pin pricks are created in IROCHouston’s conventional H&N phantom by inserting a fine needle into a small drilled hole
near the internal structures. This method was not feasible in the MRgRT H&N insert
since a fine needle could pierce through any direction inside the gel material; thus,
creating greater film registration uncertainties. Additionally, piercing a needle through
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gel material could damage the internal parts of the insert. To prevent additional
uncertainties and increase the insert’s longevity, small holes were not created in the gel
material. Rather, the insert was designed with wider exterior walls and small holes were
drilled into the solid water exterior shell.
IROC-Houston is responsible for ensuring multi-institutions are delivering
consistent treatments. One method by which IROC-Houston evaluates this consistency
is by sending anthropomorphic phantoms with detail dose prescription instructions to
institutions. With the goal of using the MRgRT H&N phantom to examine an institution’s
ability to deliver radiation consistently among other institutions, it was important that
this phantom also use the same instructions and evaluation metrics as IROC-Houston’s
conventional H&N phantom. During both commissioning and feasibility studies,
institutions were required to use a specific dose prescription and to use on-board MR
imagers to verify treatment setup. Additionally, IROC-Houston allowed institutions to
use other MR workflow components as needed. Thus, institutions were free to
incorporate MR-based treatment planning and real-time MR image guidance. While most
institutions used CT-only to create an IMRT plan, one institution (ViewRay 4) chose to
use the electron density captured on a CT image and then plan based on the MR image.
Unlike MRIdian systems, the Unity system was not equipped with lasers inside
the vault. In fact, the Unity system solely relied on capturing an MR image to account
for any setup discrepancies between each irradiation. Part of the Unity system’s
workflow required a re-optimization based on the current setup position. The
commissioning test encompassed all parts of the workflow including MR setup
verification methods. During each irradiation the treatment couch was moved outside the
bore and the insert was removed from the phantom to load new unirradiated detectors
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into the insert. Once unirradiated TLDs and film sheets were reloaded into the phantom,
the H&N insert was screwed into the phantom and the treatment couch was moved back
inside the bore. During this process, the phantom could have been moved in a slightly
different position due to the couch movement and the insert’s re-installation into the
phantom. There were no lasers to verify whether the phantom was in the same position
as the previous irradiation. To account for any movement, MR images were acquired
before each irradiation and the treatment plan was re-optimized accordingly.
Each step in the radiation treatment process will have associated uncertainties.
Since MRgRT systems have different workflows than conventional linear accelerators,
they will also have different associated uncertainties. Some of the various sources of
uncertainties could arise from: 1) MR/CT image fusion, 2) potential minor dosimetric
effects on TLDs from an MR environment, 3) linear accelerator output consistency 4)
MR geometrical accuracy and 5) re-optimization differences. While the major purpose
of these studies was not to quantify the source of uncertainties, these studies were used
to evaluate an institution’s performance based on the entire treatment process. If an
institution failed IROC-Houston’s passing criterion then it was that institution’s
responsibility to further investigate the source of errors and implement new protocols to
mitigate uncertainties from those components. Even with various uncertainties, the
gamma results from them MRgRT H&N phantom demonstrated that those uncertainties
played a minimal role in the overall dose delivery. These studies also demonstrated that
the Unity, MRIdian

60

Co, and MRIdian Linac systems have the ability to consistently

deliver IMRT treatments.
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4.6

CONCLUSION
NCI sponsored clinical trials will further investigate the impact of using MRgRT

systems for various disease sites including cancers in the H&N region. The MRgRT
H&N phantom was designed to credential institutions wishing to use IMRT techniques
with MRgRT systems. This phantom was designed to be used in all aspects of MRgRT
treatment workflows in that it was constructed using tissue equivalent materials which
could be visualized in 0.35T-1.5T MR imagers, and CT imagers. Commissioning and
feasibility studies showed high reproducibility and agreement between all MRgRT
systems, thus, indicating that the MRgRT H&N phantom would be a useful metric in
credentialing institutions participating in NCI clinical trials. Additionally, the end-to-end
test demonstrated that the Unity, MRIdian 60Co, and MRIdian Linac systems workflows
could deliver comparable advanced IMRT treatments in the H&N region.
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Chapter 5: MRgRT Thorax QA Phantom: Design,
Construction and Feasibility Study
A substantial portion of this chapter is written or based on the following publication:
A.Steinmann, P Alvarez, H Lee, R. Stafford, L. Court, Z. Wen, G. Sawakuchi, D. Fuller,
D. Followill, “MRgRT Thorax Anthropomorphic QA Phantom: Design, Development,
Commissioning and Feasibility Study,” Medical Physics. [In review] (2018). © John
Wiley and Sons.
The permission for reuse of this material was obtained from John Wiley and Sons.
5.1

ABSTRACT

Purpose: To design, manufacture and evaluate a dynamic MRI/CT compatible
anthropomorphic thorax phantom used to credential MR guided radiotherapy (MRgRT)
systems participating in NCI-sponsored clinical trials.
Method: The anthropomorphic thorax phantom was constructed from a water-fillable
acrylic shell that contained several internal structures representing radiation sensitive
organs within the thoracic region. A custom MR/CT visible cylindrical insert was
designed to simulate the left lung with a centrally located tumor target. The surrounding
lung tissue was constructed from a heterogeneous in-house mixture using petroleum jelly
and miniature (2-4mm diameter) styrofoam balls and the tumor structure was
manufactured from liquid PVC plastic. An MR conditional pneumatic system was
developed to allow the MRgRT insert to move in similar inhale/exhale motions. TLDs
and radiochromic EBT3 film were inserted into the phantom to measure absolute point
doses and dose distributions, respectively.
The MRgRT thorax phantom was evaluated through a commissioning study and
a feasibility study. Comprehensive end-to-end examinations were done where the
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phantom was imaged on a CT, an IMRT treatment plan was created and an MR image
was captured to verify treatment setup. Then, the phantom was treated on an MRgRT
system. The commissioning study evaluated the phantom’s reproducibility ease by
irradiating three times on an Elekta’s 1.5T Unity system. The phantom was shipped to
three independent institutions and was irradiated on either an MRIdian cobalt-60 (60Co)
or an MRIdian linear accelerator system. Treatment evaluations used TLDs and
radiochromic film to compare the planned treatment reported on the treatment planning
software against the measured dose on the dosimeters.
Results: The commissioning of the phantom on the Unity system resulted in reproducible
TLD doses (SD < 1.5%). The measured TLD to calculated dose ratios from the
commissioning and feasibility studies ranged from 0.93 to 1.01 and 0.96 to 1.03,
respectively. Using a 7%/5mm gamma analysis criteria, the commissioning and
feasibility studies resulted in an average passing rate of 93.3% and 96.8%, respectively.
No difference was noted in the results between the MRIdian 60Co and 6 MV delivery to
the phantom and all treatment evaluations were within IROC-Houston’s acceptable
criterion.
Conclusions: The motion enabled anthropomorphic MRgRT thorax phantom, CT/MR
visible and tissue equivalent, was constructed to simulate a lung cancer patient and was
evaluated as an appropriate NIH credentialing tool used for MRgRT systems.
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5.2

INTRODUCTION
Magnetic resonance (MR) guided radiotherapy (MRgRT) systems integrate MR

imagers with either a radioactive 60Co source or a linear accelerator. Within the United
States there are three different MRgRT clinical models, which include the MRIdian 60Co
(ViewRay, Oakwood Village, Ohio), the MRIdian Linac (ViewRay, Oakwood Village,
Ohio), and the Unity (Elekta, Crawley, United Kingdom and Philips, Amsterdam,
Netherlands)

10-13

. All of these MRgRT systems are equipped with an on-board MR

imager which has a magnetic field ranging from 0.35T to 1.5T. The MRIdian 60Co system
was the first system to treat patients in the United States and is equipped with three 60Co
head sources that are centrally located between a split 0.35T superconducting magnet.
The MRIdian Linac is an upgraded prototype of the MRIdian

60

Co system and is

equipped with a single 6 MV linear accelerator in between a 0.35T split magnet. The
Unity system is equipped with a single 7 MV linear accelerator mounted above a
modified 1.5T magnet.
MRgRT systems utilizing on-board MR imagers during treatment could
potentially revolutionize radiation therapy. Some of the most promising advancements
are: gating, target tracking and online adapted radiotherapy (ART) techniques80; 81; 91.
Inherently, MR imagers do not contribute to patient dose. This means a patient’s tumor
could be tracked during the entire treatment through a series of cine MR images without
increasing the patient’s absorbed dose. If a target structure moves outside a desired
treatment boundary, the MRgRT system can theoretically recognize this variation and
momentarily stop delivering radiation until the target moved backed into the desire
location91. MR gating techniques would most benefit tumor sites located on anatomical
structures that regularly move (i.e., lungs, pancreases, GI track). In addition to tumor
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tracking, these MRgRT systems could potentially perform online ART by capturing an
MR image prior to every treatment and recalculating a new treatment plan based on the
disease site’s response to radiation, location, and size. Online ART and MR-based
tracking could help create even more patient-specific radiation treatments by modifying
tumor margins before every treatment. As a result, these techniques can potentially
improve local tumor control and reduce normal tissue toxicity.
Clinical outcomes and applications are still being explored since the first MRgRT
system to treat a patient in the United States was in 201492. To preliminarily address
MRgRT safety concerns, the National Institutes of Health (NIH) has sponsored two
clinical trials that focused on the safety aspects of capturing MR images (NCT02973828)
and delivering radiation (NCT03284619). With on-board MR imagers having the
potential to use MR cine images to track tumors, NIH has also sponsored several shortterm single institutional studies that permit MRgRT systems to track and treat moving
disease sites located on either a liver (NCT02683200) or a lung (NCT02264886)
structure. NIH has also sponsored several limited clinical trials that used online ART
techniques. Much of these clinical trials focused on disease sites located on either lung
(NCT02264886/ NCT02950792) or breast (NCT01999062) anatomical structures. Many
of NIH sponsored clinical trials have used tumors located in the thorax region to
understand the potential applications of MRgRT systems. Larger multi-institutional
National Clinical Trial Networks (NCTN) will be sponsored by the NIH to further
investigate the clinical uses and outcomes of treating lung tumors on an MRgRT system.
Institutions participating in multi-institutional clinical trials must cohesively
deliver the same treatment protocol as other participating institutions on the trial. NIH
requires each institution to first participate in a credentialing process to demonstrate its
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ability to consistently deliver intensity modulated radiation therapy (IMRT) using a strict
treatment protocol. NIH has funded the Imaging and Radiation Oncology Core Quality
Assurance (QA) center in Houston (IROC-Houston) to credential all institutions wishing
to participate in NCTN clinical trials. During the credentialing process, IROC-Houston
ships out a standardized anthropomorphic phantom and requires the institution to follow
a standard treatment protocol that is provided by IROC-Houston. These instructions
require the institution to capture a CT simulation, create an individual treatment plan and
deliver radiation to the phantom. IROC-Houston will then evaluate the institution’s endto-end performance by comparing the treatment plan to the dose delivered on the
phantom.
IROC-Houston has an assortment of site-specific anthropomorphic phantoms.
Depending on the clinical trial, IROC-Houston will ship either a head and neck (H&N),
thorax, spine, liver, or prostate anthropomorphic phantom to an institution for an off-site
credentialing test. IROC-Houston’s conventional thorax phantom is the second most
common phantom used to credential institutions and is described in detail by Followill et
al. 200759. In short, the conventional thorax phantom is a water-fillable shell that contains
several internal structures. Inside the thorax-shape external shell, the phantom is
equipped with two lungs manufactured of compressed cork, an acrylic spinal cord and a
nylon heart. The left ipsilateral lung was designed as an attachable insert that can connect
to a motion table. The insert movement simulates patient breathing by regularly moving
every three seconds. The conventional lung insert was designed with a single tumor
manufactured from high impact polystyrene (HIPS) and was centrally located around
surrounding lung mimicking tissue that was manufactured from compressed cork.
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Integrating an MR imager with a radiotherapy system will inherently change the
overall workflow. As described in the Steinmann et al. study, IROC-Houston’s
conventional thorax phantom was constructed with hydrogen deficient materials72. The
lack of hydrogen creates a lack of MR signal between the tumor and surrounding tissue
materials, thus, causing the two structures to be indistinguishable in a MR image.
Additionally, the motion table used to simulate patient breathing is MR unsafe since it
contains ferromagnetic materials. If the motion table is placed too close to the MR
system, the ferromagnetic materials would become magnetized and would dangerously
project into the MR system. If the motion table’s rotary motor was positioned far away
from the magnetic field (i.e., past the 5 G line) and was turned on, it would still affect the
MR components since the induced magnet field would interfere with the acquired signal
and distort the MR image. Therefore, IROC-Houston’s conventional thorax phantom and
motion table are completely inadequate for use in MR environments and a new MRgRT
thorax phantom and motion system must be developed for MRgRT workflows so that
they are safe to use in an MR system and all of their internal structures are
distinguishable.
Current studies have attempted to manufacture MR/CT compatible thorax
phantoms, but they do not fit IROC-Houston’s off site anthropomorphic phantom
requirements. IROC-Houston’s phantoms must contain multiple internal structures (i.e.,
tumor, heart, contralateral lung, spinal cord) and use passive dosimeters. Specifically, for
MRgRT workflows, the phantom materials also must be MR/CT visible, tissue
equivalent, durable, and they must require minimal maintenance and storage conditions57;
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. To the author’s knowledge, there are only three MR/CT compatible thorax phantom

designs that use synthetic materials. The MRI-LINAC Dynamic thorax phantom (CIRS,
104

Norfolk, Virginia, USA) contains two sections: the superior part is a grid used to quantify
MR geometrical distortions and the inferior part attempts to create a very simplistic
phantom with a moving target. The inferior portion of the phantom has a single
cylindrical-shape air cavity which is not a realistic simulation of a lung with a moving
MR target. This phantom does not anatomically represent the thorax since it does not
contain critical organs (i.e., spinal cord, heart, and contralateral lung). The target is
attached to a rigid extended shaft that is connected to a stepper motor. The stepper motor
itself contains ferromagnetic materials and is considered MR unsafe. If this stepper motor
is placed too close to the bore, it could become magnetized and dangerously project into
the MRgRT system. Therefore, this phantom is not ideal for IROC-Houston since it does
not contain multiple internal structures and the motor is MR unsafe.
The other two MR/CT compatible thorax phantoms, which used synthetic
materials, are similarly designed and contain a water-fillable acrylic shell with limited
internal structures. The PET/MRI/CT Compatible Respiratory Tumour Motion Phantom
(CRTMP) (Shelley Medical Imaging Technologies, London, Ontario, Canada) consist of
two equally spaced cylindrical air cavities representing lungs and a fillable cylinder
representing a spinal cord. Inside one of the air cavities is a fillable spherical tumor that
connects to an MR safe motor. The QUASAR™ MRI4D motion phantom consists of two
asymmetric cylindrical inserts and was not designed with other important critical
structures (i.e., heart or spinal cord). Additionally, the QUASAR™ MRI4D phantom does
not anatomically represent two lungs since the created air cavities are adjacent to each
other with little separation. The center air cavity is equipped with a fillable spherical
tumor that connects to an MR safe motor. Both CRTMP and QUASAR™ MRI4D
phantoms are similarly designed with a customizable insert that mimics tumor motion
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with an MR safe ceramic piezoelectric motor. These phantoms only show a single
contrast (i.e., absent signal vs. water signal) in an MR image. While MR contrast agents
(i.e., gadolinium) could be used to add additional contrast, the contrast has a high atomic
number and would not dosimetrically resemble tissue. These phantoms did not meet
IROC-Houston’s requirements since they lack organ at risk (OAR) structures and are not
equipped with portable dosimeters.
The aim of this study was to design, manufacture, and evaluate an MR/CT
compatible, dynamic anthropomorphic thorax phantom used as an end-to-end test for
MRgRT systems.
5.3

MATERIAL AND METHODS
The MRgRT thorax phantom and motion system were designed to meet IROC-

Houston’s radiotherapy, diagnostic imaging and practicality criteria. To meet
radiotherapy and diagnostic criterion, materials used in the phantom were selected based
on their ability to structurally represent human anatomy, be visible in both MR and CT
images and be tissue equivalent. Practicality criteria were met in the phantom by selecting
materials that maintained constant shape, required minimal maintenance, and were made
with synthetic materials that did not require additives. For the practicality criteria of the
motion systems, the motion parts used in the treatment vault needed to be MR safe and
easily connect to the thorax phantom. Once designed and manufactured, the MRgRT
thorax system was reproduced on a single Unity system and sent out to three institutions
for a miniature multi-institutional feasibility study.
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5.3.1

Phantom Design
All internal structures in the conventional thorax phantom, except the ipsilateral

lung and tumor, were distinguishable in an MR image since the MR signal from water
outlined their shapes. IROC-Houston’s conventional thorax phantom was modified so
that the entire thorax phantom could be used in an MRgRT workflow. These
modifications included: 1) a new MRgRT lung insert and 2) an MR safe motion system.
The MRgRT thorax phantom was designed to resemble closely human anatomy
by constructing several shapes to represent internal structures and to mimic IROCHouston’s current photon thorax phantom. The thorax phantom was manufactured with
an external water-fillable PVC shell (The Phantom Laboratory, Salem, New York, USA)
and contained four internal structures which geometrically represented a spinal cord, a
heart and two lungs. The right contralateral lung, spinal cord and heart were immobile
structures whereas the left ipsilateral lung was designed to connect to a motion system
so that it could simulate patient breathing. A platform with a 15 degree inclination was
connected to the exterior shell to create anterior-posterior and superior-inferior motion.
Figure 28 displays the MRgRT thorax phantom compartments which include: the exterior
phantom, the 15-degree platform, the attachable ipsilateral lung insert’s shell and the four
individual lung pieces.
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Figure 28: The MRgRT Thorax Phantom. The phantom consists of a water-fillable
anthropomorphic thoracic shell, an inclining 15-degree platform and an external insert shell
that holds four individual MR/CT compatible insert pieces.

Figure 29: A CT image of the center of an MRgRT thorax phantom. Inside the acrylic shell
are a contralateral lung, an ipsilateral lung, a heart, and a spinal cord structure. The PTV is
located at the center of the ipsilateral lung. Sagittal and axial radiochromic films are
inserted into the ipsilateral lung. Each heart and spinal cord structure holds a single TLD
and the PTV holds two (superior and inferior) TLDs.
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The OAR structures were manufactured using acrylic, nylon, and compressed
cork for the spinal cord, heart and contralateral lung structures, respectively. The heart
and spinal cord were each designed to hold a double-loaded TLD. The materials used in
the MRgRT lung insert were selected from the Steinmann et al. 2018 study72. The
ipsilateral lung had an outer diameter of 12.5 cm and a length of 19 cm and was
constructed with an in-house heterogeneous mixture of 8.3% wt. of 2-4 mm styrofoam
balls and 91.7% wt. of petroleum jelly. The in-house heterogeneous mixture was
encapsulated in high impact polystyrene (HIPS). Centrally located in the lung insert was
a prolate spheroid which represented the tumor and had a major and minor diameter of
10 cm and 5 cm, respectively. The tumor was constructed with 100% liquid PVC plastic
that was encapsulated with solid water and held two double-loaded TLDs.
Table 19 summarizes the internal structures’ materials, dimensions, and total TLD used
and Figure 29 displays an axial CT image of the internal structures.
The MRgRT lung insert was composed of four individual pieces which combined
into a single unit when a HIPS shell was used to secure the pieces in place. Alignment
notches were built into the individual lung pieces and the HIPS lid to create a unique
reproducible orientation. The HIPS lid was also constructed with an aluminum rod which
was designed to connect to part of the pneumatic system and not interfere with the target’s
dose delivery. The MRgRT lung insert allowed radiochromic films and TLDs to be
inserted centrally to the tumor. A total of three radiochromic films were installed into the
MRgRT lung insert. Two radiochromic films captured the sagittal plane by placing each
film at the superior and inferior parts of the insert. A single film was placed in between
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the sagittal planes to capture an axial plane. Double-loaded TLDs were installed at the
centers of the superior and inferior pieces.

Diameter
(cm)

Length
(cm)

100% Liquid PVC Plastica
In-house Petroleum Jellyb
Styrofoam ballc mixture‡
Compressed Corkd

4
12.5

5
18

Total
TLDs
Used
2*
-

12.5

18

-

Acrylice

1

13

1

Nylond

8

-

1

Structure

Material

Primary PTV
Ipsilateral
Lung
Contralateral
Lung
OAR: Spinal
Cord
OAR: Heart

a: M-F Manufacturing Company, Fort Worth, Texas, b: Sonneborn, Parsippany, New Jersey, USA c: Steve Spangler
Science Styrofoam Beads, Englewood, Colorado, USA, d: McMaster-Carr, Elmhurst, Illinois, USA, e: Professional Plastics,
Fullerton, California, USA
‡:In-house mixture that used 8.3% weight of Styrofoam balls and 91.7% weight of petroleum jelly.

*: One TLD was inserted in the superior piece and the other TLD was inserted into the inferior piece.

Table 19: The materials used to manufacture the MRgRT thorax phantom.

5.3.2

Pneumatic Motion System Design
IROC-Houston’s conventional photon lung phantom is moved physically to

mimic breathing patterns by attaching a programmable stepper motor/bi-slider system to
a motion platform on which the phantom rests. The stepper motor system components
are classified as MR unsafe materials since they contain ferromagnetic materials. A
pneumatic system was designed as an alternative way to represent breathing motion
inside an MR environment. The schematic of the pneumatic system used for the MRgRT
thorax phantom is shown in Figure 30. A compacted 1.5 L air compressor (Model#:
D55140, DeWalt, Baltimore, Maryland, USA) was used to constantly supply air to a 3way valve (Part#: S20U30-SS-11-2, Bimba, University Park, Illinois, USA) which was
manually controlled through a physical on/off electric switch (Model#: R62-02653-02W,
Leviton, Melville, New York, USA). When the electric switch was positioned off, the 3-
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way valve would naturally release air to the exhaust pipe. If the electric switch was
flipped on, the 3-way valve would electrically close the exhaust pipe port and open the
4-way valve port (Part#: N2-SCD-120-VAC, Bimba, University Park, Illinois, USA).
When the port was open, the 4-way valve supplied air to the cylinder which physically
moved the MRgRT lung insert. Additionally, the red and blue plastic nylon tubing (Part#
4HHC8, Granger, Lake Forest, Illinois, USA) attached to the 4-way valve were used to
control the air flow supply on the cylinder. The blue tubing represented expiration
whereas the red tubing represented inspiration. An electrical time delay counter (Model#
IO23B01, Ebay Item# 232013288409, Ebay, San Jose, California, USA) was used to
regulate the 4-way valve air flow direction. This 110V timer was programmed to
fluctuate the air supply between the inhale (red) and exhale (blue) tubing every three
seconds. Both exhale and inhale tubing were connected to a flow control knob (Part#:
RAFK-2x2, Bimba, University Park, Illinois, USA). The knobs were used to manually
control the speed at which the lung insert would move by adjusting the air flow pressure.
The inhale (red) and exhale (blue) plastic tubing were connected to an MR safe cylinder
(Part#: FOD-040.8-ABBMT, Bimba, University Park, Illinois, USA). The cylinder was
modified with a custom brass piston to make it MR safe and was specially designed to
connect to the HIPS lid. The piston physically moved the lung insert according to the air
flow direction. When the red tubing supplied pressurized air, the piston would extend
and cause the lung insert to move inferiorly. Vice versa, the piston would contract and
move the lung insert superiorly when the blue tubing supplied pressurized air.
As illustrated in Figure 30, the equipment used in the pneumatic system was
divided into two broad sections: MR safe and MR unsafe parts. The MR safe parts could
be used inside the MRgRT treatment vault and included: the cylinder, the piston, the lung
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insert and the plastic tubing. MR unsafe materials were required to stay outside the vault
and these parts were: the compressor, the 3-way valve, and the 4-way valve. The red and
blue plastic tubing were placed through the MR waveguide; thereby creating a physical
wall barrier between MR safe and MR unsafe parts of the pneumatic system. The cylinder
was screwed directly into the MRgRT thorax phantom and during treatment was placed
at the center of the bore.

Figure 30: Schematic of the pneumatic system used to mimic lung motion in a MR
environment. The pneumatic system was broadly divided into two sections: MR safe and MR
unsafe parts. MR safe parts were allowed inside the treatment vault whereas MR unsafe
parts were stored outside the treatment room. The MR unsafe parts consisted of the air
compressor and parts used to regulate the air flow. The MR safe parts included the plastic air
tubing and a custom cylinder. The two tubes were colored red and blue to distinguish the air
flow used to move the cylinder’s brass piston. The red tubing represented inspiration and
blue tubing represented expiration.

5.3.3

Phantom Imaging
The MRgRT thorax phantom was imaged on a CT simulator and two MRgRT

systems using 1.5T and 0.35T magnetic field strengths. Under a GE Lightspeed CT
simulator (General Electric Company, New York, New York, USA), the phantom was
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imaged using a breast protocol with scanning parameters of: DFOV= 500.0 mm, 120
kVp, 275 mA, and slice thickness=3mm. The MRgRT thorax phantom was imaged on a
1.5T Unity system using a T1-weighted sequence and had scanning parameters of: FA=
8°, TR= 8.0 ms, TE= 3.6 ms, ETL= 136, NEX=1. Using a 0.35T MRIdian

60

Co, the

MRgRT thorax phantom was scanned with a TrueFISP (true fast imaging with steadystate free precession) sequence and had scanning parameters of: FA= 60°, TR= 3.33 ms,
TE= 1.43 ms, NEX=1. The MR scanning parameters from the Unity and MRIdian
systems are summarized in Table 20.

Parameters

ViewRay

Unity

MR Scanning
Sequence

True Fast Imaging
T1-Weighted
with Steady-state free
Gradient
Precession (TrueFISP)
FA
60°
8°
TR (ms)
3.33
8.0
TE (ms)
1.43
3.6
ETL
136
NEX
1
1
Table 20: MR images were captured on both the ViewRay and Unity systems. The ViewRay
system acquired a true fast imaging with steady-state free precession image and the Unity
system acquired a T1- weighted image. *TRUFI and TrueFISP are the same sequences but
are under different names for different manufactures.

5.3.4

Dose Prescription
The dose prescriptions set for the MRgRT thorax phantom were the same

prescriptions used for IROC-Houston’s conventional thorax phantom. In short, 95% and
99% of the primary tumor volume (PTV) were required to receive at least 6.0 Gy and 5.4
Gy, respectively. Excluding the PTV, 37% of the whole lung (i.e., both left and right
lung) was restricted to receive a maximum of 2.0 Gy. The spinal cord and heart had
maximum received dose limits of 5.0 Gy and 4.0 Gy, respectively. Additional dose
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constraints limited 6.0 Gy and 4.5 Gy to 33% and 66% of the heart volume, respectively.
IROC-Houston’s dose prescriptions for the MRgRT thorax phantom are summarized in
Table 21.
MRgRT Thorax
Structure

Dose Prescription

PTV

D95% ≥ 6.0 Gy
D99% ≥ 5.4 Gy

Whole Lung
(Contralateral &
Ipsilateral)
OAR: Spinal Cord

D37% < 2.0 Gy

D0% ≤ 5.0 Gy
D33% ≤ 6.0 Gy
OAR: Heart
D66% ≤ 4.5 Gy
D100% ≤ 4.0 Gy
Table 21: The dose prescription for the MRgRT thorax phantom. Both commissioning and
feasibility studies used the same dose constraints.

5.3.5

Treatment Delivery
The MRgRT thorax phantom was reproduced using a 1.5T Unity system and then

sent out to three institutions for an independent feasibility study. During the multiinstitutional feasibility study, the MRgRT thorax phantom was irradiated using either an
MRIdian Linac or an MRIdian 60Co and Unity MRgRT system. The performance of both
reproducibility and feasibility studies were evaluated based on an end-to-end test.
Double-loaded TLDs (ThermoFisher Scientific, Waltham, Massachusetts, USA)
were read two weeks from the irradiation date to account for fading. These absolute
dosimeters were read with the same method as IROC-Houston uses for its phantom
studies. The amount of lithium fluoride powder was read using a Mettler AT261
DeltaRange (Mettler Toledo, Greifensee, Switzerland) scale and a Harshaw M3500 TLD
reader (ThermoFisher Scientific, Waltham, Massachusetts, USA) was used to measure
the light output. Additionally, the MRgRT thorax phantom used EBT3 film as relative
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dosimeters. The intensity from the irradiated films was read on a photoelectron CCD
microdensitometer (Photoelectron Corporation, North Billerica, Massachusetts, USA)
and converted into dose using an in-house MATLAB program (The MathWorks, Inc.,
Natick, Massachusetts, USA).
The end-to-end tests for reproducibility and feasibility studies were analyzed by
using the same two evaluation methods. These analytical methods included: 1)
comparing measured TLD dose to expected plan and 2) performing a gamma analysis
using a 7%/5mm criterion.

5.3.5.1 Reproducibility Study
During the reproducibility study, the MRgRT thorax phantom was irradiated
three times on a 1.5T Unity system. The exterior thorax shell was filled with tap water
and imaged on a GE Lightspeed CT simulator using a breast protocol. The parameters of
this protocol were: DFOV= 500.0 mm, 120 kVp, 275 mA, and slice thickness= 3mm.
The electron density data collected from the CT simulator was transferred to Monaco’s
Treatment Planning Software (TPS) (Elekta, Crawley, United Kingdom) and an IMRT
plan was designed using 7 beams angles. All anatomical structures and TLD capsules
were contoured and labelled accordingly.
The MRgRT thorax phantom was placed above a 15-degree inclining platform
and was positioned in the center of the Unity’s treatment couch. The surface coil did not
properly fit over the phantom and platform; so, the Unity’s body coil was used to capture
a MR image. The treatment setup used in the reproducibility study for the thorax phantom
is shown in Figure 31. New dosimeters were replaced in the thorax phantom after each
irradiation. To reload new radiation detectors the treatment couch was moved out of the
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bore, the pneumatic system was momentarily switched off to release pressurized air and
the lung insert was removed from the phantom. Once the portable dosimeters were
replaced, the insert and the pneumatic system were screwed back to the phantom, the
pneumatic system was turned on, and the phantom was moved back into the center of the
bore. A T1-weighted MR image was captured using scanning parameters of: FA= 8°,
TR= 8.0 ms, TE= 3.6 ms, ETL= 136, NEX=1 after every irradiation. The treatment plan
was re-optimized based on the MRgRT thorax’s current position and then irradiated.
Each irradiation took approximately 30 minutes to deliver all 7 beams. TLD capsules’
maximum, minimum and mean doses were recorded, and the treatment plan was exported
to further analyze the treatment performance.

Figure 31: The MRgRT Thorax Phantom setup up for the reproducibility study. The
MRgRT body coil was used to capture an MR image.

5.3.5.2 Feasibility Study
The MRgRT thorax phantom was shipped to three institutions within the
United States that either had an MRIdian

60

Co or an MRIdian Linac MRgRT
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system. In addition to receiving the thorax phantom and the pneumatic system, each
institution received from IROC-Houston detailed instructions describing how to use the
motion system and the dose prescriptions requirement. Upon receiving the phantom, the
institutions were required to perform an end-to-end test. This test required each
institution to image the thorax phantom on a CT, create a treatment plan based on IROCHouston’s dose prescriptions, capture an MR image to verify treatment setup and, finally,
irradiate the phantom. Since this end-to-end test was to demonstrate the ability to treat a
moving target, IROC-Houston required each institution to use the pneumatic system
during imaging and treatment stages. Institutions were allowed to emulate their typical
MR workflow by choosing gantry angles, type of motion management, and any
additional MR workflow components. Each institution was required to submit a digital
copy of the treatment plan and record the expected TLDs’ maximum, minimum, and
mean dose. End to end tests were analyzed by evaluating the treatment plan to measured
dose.

5.4
5.4.1

RESULTS
Phantom Imaging
As shown in Figure 32, the MRgRT thorax phantom was imaged on a GE CT

simulator, and Unity and MRIdian MRgRT system. Internal structures and the disease
site are clearly visible in all three images. The contralateral lung, heart, and spinal cord
were constructed of non-MR visible materials. The absence of MR signal in these internal
structures could be seen due to the contrast between the lack of signal surrounded by the
MR signal from water. The ipsilateral lung and disease site were constructed of MR
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visible materials and the contrast between these structures was visible on all three images.
On the Unity system, the disease site appears brighter and has a higher spatial resolution
which is attributed to the magnetic field strength and MR sequence, respectively. The
Unity system used a T1-weighted sequence whereas the MRIdian system used a true fast
imaging with a steady-state free precession (TrueFisp) sequence.

a.

b.

c.

Figure 32: The MRgRT thorax phantom was filled with water and scanned on: (a) GE CT
simulator, (b) Unity system’s 1.5T MRI with a T1 sequence and (c) ViewRay’s MRIdian 60Co
0.35T system with a TrueFISP sequence. In all images, the OAR, primary and secondary
PTV are clearly visible.

5.4.2

Treatment Delivery
In both the commissioning and the feasibility study, measured TLD dose was

compared to predicted dose from the TPS. Table 22 and Table 23 display the ratios
between measured and predicted dose under the commissioning and feasibility study,
respectively. TLDs within the superior portion of the PTV had ratios of: 1.00, 1.01, and
1.00 and in the inferior portion had ratios of: 0.93, 0.98, and 0.96 for the commissioning
study. Overall, the average ratios between measured and reported doses for superior and
inferior PTVs locations were 1.00 and 0.96, respectively. The feasibility study showed
greater agreement between measured and expected dose at the inferior PTV than did the
commissioning study. The superior portion of the PTV had ratios of: 0.98, 1.03, 1.00,
whereas the inferior portion had ratios of: 1.00, 1.00, and 0.98. TLDs that fall within 0.92
118

and 1.05 to reported dose were considered to pass IROC-Houston’s TLD dose criterion.
In both studies, TLD readings were within IROC-Houston’s acceptable criteria.

Reproducibility Test

TLD Location

Average

Coefficient of
Variance

Unity 1-a
Unity 1-b
Unity 1-c
PTV Superior
1.004
1.006
1.000
1.004
0.3%
PTV Inferior
0.934
0.982
0.961
0.959
2.5%
Table 22: The reproducibility test results of two PTV TLD positions. The left column
represents TLD locations for doses calculated on Monaco’s treatment planning software.
The middle three columns represent the average TLD measured for each location and the
percent standard deviation. The average ratios between measured and calculated dose are
displayed in the right column. The TLD measurements were all within 4.1% of the reported
TLD dose and the coefficient of variance was all within 2.5%.

Institution

Energy

PTV
Superior

PTV
Inferior

Unity 1

7 MV

1.00

0.96

ViewRay 2

6 MV

0.98

1.00

1.03

1.00

ViewRay 3

60

Co

60
ViewRay 4
Co
1.00
0.98
Average
-1.00
0.98
Table 23: Feasibility study results for two TLD positions in the PTV for the MRgRT thorax
phantom. The results display ratios between measured TLD dose and reported TLD dose
from the institutions’ treatment planning software.

IROC-Houston evaluated the treatment deliveries by performing an in-house
gamma study on axial and sagittal films. The same gamma criteria (7%/5mm) used on
IROC-Houston’s conventional thorax phantom was also used to evaluate the MRgRT
thorax phantom. A film was said to pass the gamma analysis if more than 80% of the
pixels passed each axial and sagittal plane and if the combined average between the two
films (sagittal and axial) resulted in at least 85% of pixels passing. Table 24 and Table
25 display the individual gamma pass rates for both the commissioning and the feasibility

119

study, respectively. The commissioning study had individual passing rates of 89.0%,
96.8%, and 96.1% for axial films and 90.4%, 96.8%, and 90.9% for sagittal films.
Individual passing rates for axial films were 97.9%, 96.7% and sagittal films were: 95.7%
and 96.6% in the feasibility study. The combined average of pixels passing between axial
and sagittal film in the commissioning study were 89.7%, 96.8%, 93.5% and were 96.8%
and 96.7% in the feasibility study. Three dose profiles were generated in anteriorposterior, left-right, and superior-inferior orientations during gamma analysis. A typical
set of dose profiles generated from the study is shown in Figure 33. Qualitatively, film
dose profiles in all studies were in excellent agreement with their calculated dose profiles.
% Pixel Passing
[7%/5mm]
Institution
Axial
Sagittal
Average Film Plane
Unity 1-a
89.0
90.4
89.7
Unity 1-b
96.8
96.8
96.8
Unity 1-c
96.1
90.9
93.5
Average
94.0
92.7
93.3
Table 24: The MRgRT thorax phantom was irradiated three times under a 1.5T Unity
system. Axial and sagittal planes were evaluated based on 7%/5mm gamma criteria.

Institution

Energy

Axial

Pixel Passing
Sagittal
Average
Film
Plane
95.7%
96.8%
96.6%
96.7%

ViewRay 2
6 MV
97.9%
ViewRay 3
Co-60
96.7%
*
ViewRay 4
Co-60
Average
97.3%
96.2%
96.8%
Table 25: The feasibility study were evaluated using the same passing criteria as the
commissioning study. IROC-Houston gamma passing criteria required individual film planes
to have a greater than 80% passing rate and an overall passing rate of 85%. *Data
unavailable from institution for analysis.
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a.

b.

c.

Figure 33: Dose profiles generated in the (a) anterior-posterior, (b) left-right, and (c)
superior-inferior direction. These graphs compare dose profiles generated on film to those
generated from the treatment planning. These graphs were generated from institution 3, but
resemble the typical dose profiles generated from both the feasibility and the commissioning
studies.

121

5.5

DISCUSSION
IROC-Houston’s conventional thorax phantom was originally designed for CT-

only workflows and was not intended to be used in MR environments. Two primary
concerns with IROC-Houston’s conventional thorax phantom that rendered the phantom
insufficient for MRgRT systems. These concerns were: 1) PTV and surrounding tissues
were indistinguishable in MR images and 2) the motion table contained ferromagnetic
materials that classified the motion system as MR unsafe. It was critical that the disease
site and surrounding tissues were distinguishable from one another since on-board MR
imagers can track tumors during treatment. Since IROC-Houston’s phantoms evaluated
the institutions’ ability to accurately deliver radiation, it was also important that the
MRgRT thorax phantom simulate patient breathing. Having motion during imaging and
radiation delivery allowed institutions to perform their normal MR clinical workflows
and allowed them to determine methods to mitigate motion uncertainties (i.e., gating,
tumor tracking, free breathing).
Several design modifications were performed to create an MRgRT lung insert
which included: 1) creating four insert pieces, 2) equipping the insert with film pinpricks,
and 3) construction of an exterior insert shell used to create a single unit. The MRgRT
lung insert was constructed using a heterogeneous mixture which was composed of semisolid petroleum jelly and miniature styrofoam balls. Unlike IROC-Houston’s
conventional lung insert, where the compressed cork was sculpted into place, the MRgRT
lung insert could not simply be sculpted since the heterogeneous material was pliable.
Each insert piece had an exterior shell constructed of HIPS and was used to create a rigid
structure. The tumor was encapsulated in solid water to create a rigid structure. Solid
water was used rather than HIPS for the tumor’s exterior shell since liquid PVC plastic
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chemically reacted to HIPS. Film pinpricks are traditionally used in IROC-Houston’s
phantoms to register the film’s orientation relative to the phantom’s position. Film
pinpricks in IROC-Houston’s conventional lung insert are created by drilling small holes
through compress cork. Drilling a hole through the MRgRT lung insert was not efficient
since the insert was made with a semi-solid mixture which would make reproducing the
same pinprick location difficult. The insert was modified by securing small fine needles
inside the external HIPS part. When the insert’s pieces were combined, the small needles
created small pinprick artifacts on the film which were used to register the film position.
An exterior HIPS shell was created to combine the four individual lung insert pieces into
a single unit. The exterior shell’s lid was made with an aluminum rod used to connect the
cylinder to the lung insert.
IROC-Houston is responsible for ensuring that quality is maintained within
NCTN clinical trials. One-way IROC-Houston ensures quality is by sending off-site
credentialing phantoms to test the cohesiveness between institutions. Since consistency
is critical for the credentialing process, the MRgRT must use the same dose prescription
and passing criteria as the conventional thorax phantom. Consistent dose prescriptions
are also important when evaluating the treatment delivery. The commissioning study
consistently showed larger discrepancies between inferior portions, most likely due to
uncertainties occurring when creating the treatment plan. The thorax phantom only used
free-breathing techniques and captured the PTV’s position at a single point in time. The
treatment most likely did not capture the entire movement and caused greater
uncertainties.
The Unity system was not equipped with lasers inside the treatment vault. Rather,
this MRgRT system captured MR images during every irradiation to account for any
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setup discrepancies. Unlike conventional linear accelerators, the normal workflow for
the Unity system is to fuse an MR image to a CT image and re-optimize the treatment
plan based on the anatomical structures captured in the MR image. In the commissioning
study, the thorax phantom was removed from the MRgRT bore and the lung insert was
uninstalled after each irradiation. These changes could have introduced setup
uncertainties which included 1) the treatment couch potentially stopped at a different
location inside the bore or 2) the thorax phantom shifted from the original position once
reinstalling the insert and pneumatic system. Without lasers in the vault, it was difficult
to quantify any noticeable shifts between irradiations. To account for any setup
uncertainties and capture the entire end-to-end workflow, an MR imager was captured
after every irradiation and the treatment plan was re-optimized according to any new
shifts.
Each part of the treatment workflow will have associated uncertainties. Since
MRgRT and conventional linear accelerator systems have different workflows, they also
will have different associated uncertainties. Some inherent uncertainties of an MRgRT
system from treating a moving target on an MRgRT system would include: 1) MR/CT
image registration, 2) potential minor MR effects on TLDs, 3) MR spatial accuracy, 4)
real-time image guidance, and 5) re-optimization plans. The purpose of this study was
not to quantify the source of uncertainties, but to allow these end-to-end studies to have
similar uncertainties found in the clinic. This study showed that the Unity, the MRIdian
60

Co, and the MRIdian Linac systems consistently deliver expected treatments despite

having multiple sources of uncertainties associated to each MRgRT system. Even though
there were associated uncertainties in each step of the treatment process, the gamma
results showed that these uncertainties played a minor role in the overall dose delivery.
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5.6

CONCLUSION
In the future, NCI-sponsored clinical trials will begin to focus on the clinical

impacts of MRgRT systems. The thorax region will be of particularly interest for MRgRT
systems since new image guidance and online ART techniques could be used to improve
lung tumor radiotherapy treatments. The MRgRT thorax phantom was carefully designed
as a credentialing tool for MRgRT systems participating in NCTN clinical trials. OARs
in the MRgRT thorax phantom were distinguishable in MR due to the contrast between
the lack of signal from the internal structures and the surrounding MR signal from water.
The MRgRT lung insert has a centrally located PTV surrounded by lung-mimicking
tissue and was manufactured with tissue equivalent and MR/CT visible materials.
Commissioning and feasibility studies were within IROC’s 7%/5mm passing criteria,
thus, demonstrating that the MRgRT thorax phantom could be used as a credentialing
tool for NCI clinical trials. This study also showed that various MRgRT systems could
deliver comparable IMRT dose plans for moving targets.
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Chapter 6:
6.1

Summary

GENERAL DISCUSSIONS AND CONCLUSIONS

The main purpose of this study was to design a stationary H&N and dynamic
thorax anthropomorphic QA phantom that could be used as an end-to-end tool to
credential institutions wishing to use an MRgRT device to participate in NCI-sponsored
clinical trials. This study was completed in four independent aims. The first two aims
were designed to determine materials and radiation detectors used in the
anthropomorphic MRgRT phantoms. Once materials were chosen and detectors were
characterized in 0.35T and 1.5T magnetic field environments, then the next two aims
focused on designing, manufacturing and evaluating the anthropomorphic thorax and
H&N phantoms.
The purpose of the first aim was to identify materials that could be used to
manufacture the two MRgRT anthropomorphic phantoms. IROC-Houston had several
material requirements which included: 1) simulate soft tissue or lung tissue
dosimetrically, 2) have comparable HUs, 3) be visible in all aspects of the MRgRT
workflow (i.e., MR and CT compatible), 4) endure harsh shipping conditions, 5) show
longevity without additivities, 6) maintain physical structure over time (i.e., did not
morph over time and had high melting points), 7) show ease in manipulating into tissue
shapes and 8) hold radiation detectors in place. Before examining any dosimetric and
imaging characteristics, all materials were first examined based on their physical
characteristics. Materials that did not meet IROC-Houston’s practical characteristics (i.e.,
had low melting points, used preservatives, or required refrigeration) were eliminated as
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potential MRgRT materials. The remaining 80 materials were analyzed based on IROCHouston’s radiotherapy criterion. Most of the materials evaluated in MR and CT imagers
showed comparable HU values as human tissue but were not visible in both T1-weighted
and T2-weighted MR sequences. Silicone-based and synthetic gel-based materials were
the most promising materials since they were compatible in MR and CT. Silicone-based
materials did not dosimetrically compare to either soft tissue or lung tissue. The
dosimetric discrepancies found in silicone-based materials were attributed to their high
effective atomic numbers. Synthetic gel-based materials showed similar effective atomic
numbers and dosimetrically resemble human tissue. The first aim found four materials
(ClearBallistic Gel #20, Liquid PVC plastics, Superflab and an in-house petroleum
jelly/styrofoam ball mixture) that met all of IROC-Houston’s material requirements. Gel
#20, and 100% Liquid PVC Plastic, and Superflab dosimetrically mimicked soft-tissue
and the in-house petroleum jelly/styrofoam balls dosimetrically mimicked lung tissue
(Figure 16 and Figure 17).
TLD and radiochromic films were characterized in ViewRay’s MRIdian 60Co and
Elekta’s Unity MRgRT systems in Aim 2. The same MRgRT system was used to
characterize double-loaded TLD-100s and EBT3 film in the presence and absence of
magnetic fields for the Unity and MRIdian configurations. TLDs were characterized in
IROC-Houston’s homogenous acrylic output blocks and two geometrical phantom slabs.
A lung and head geometrical slab phantom was manufactured from materials
recommended in Aim 1. The TLD reproducibility study showed negligible differences
of 0.6% and 0.5% between TLDs irradiated in the presence and absence of MRIdian and
Unity configurations, respectively. Similarly, TLDs irradiated in geometrical phantom
slabs also showed less than 1.4% differences. A larger discrepancy was seen in the
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geometrical head phantom slab for the Unity configuration. This discrepancy resulted
from having to change the HIPS exterior wall to solid water between irradiations. TLD
comparisons using acrylic blocks and geometrical slab phantoms were all within the
2.3% TLD uncertainty and were comparable to previous studies (Table 9)65. If a magnetic
field dosimetrically affected the dose deposition in double-loaded TLDs, they were
smaller than the 2.3% TLD uncertainty and were indistinguishable from the readout
uncertainty.
In addition to double-loaded TLDs, the geometrical phantoms were used to
characterize EBT3 films in the presence and absence of a magnetic field for both
MRIdian and Unity systems. Relative beam profiles were measured on the EBT3 films
and were validated from virtual beam profiles generated on GEANT4. The DTA between
measured and generated beam profiles were compared on the Unity system. The Unity
configuration had excellent agreement between measured and generated film, thus
demonstrating that a 1.5T magnetic field environment did not affect radiochromic EBT3
film (Table 10 and Figure 21). The measured and simulated beam profiles on the
MRIdian configuration had greater discrepancies than the Unity configuration. Greater
agreement was found on the Unity configuration since the point-source file was provided
by Elekta. A generic 60Co phase-space data was used to simulate MRIdian’s proprietary
system. Using a generic
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Co phase-space data caused greater discrepancies since the

MRIdian treatment head could not be simulated completely due to unavailability of
proprietary information. The greatest discrepancy between measured and simulated beam
profiles were most apparent in the penumbra region. The simulated penumbra was
broader due to only simulating a single MLC set. EBT3 was validated in a 0.35T
environment by comparing the DTA between 0T/0.35T for measured beam profiles to
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DTA between 0T/0.35T of Monte Carlo generated beam profiles (Table 11 and Figure
22). This validation showed negligible differences between the film shift; thus,
concluding that a 0.35T environment does not affect EBT3 films.
Aim 3 used results from the previous two aims to construct anthropomorphic
thorax and H&N phantoms using materials and dosimeters previously characterized in
Aim 1 and Aim 2 (Figure 23 and Figure 28). Gel-based materials used in the MRgRT
inserts were more difficult to manufacture than solid hydrogen-lacking materials used in
IROC-Houston’s conventional inserts. Creating film pinprick locations and forming
complex structures from gel-based materials was a challenging aspect during the
manufacturing process. Film pinpricks were created by either drilling small holes into
the insert’s thicker exterior wall or by attaching permeant fine needles into the insert’s
exterior shell. Complex internal structures, constructed from gel-based materials, were
manufactured in a multi-step process. The construction process consisted of melting the
materials and pouring them into a pre-constructed custom mold. To eliminate bubbles
induced in the pouring process, the molds were placed into a vacuum until the melted
materials had solidified at room temperature. All gel-based materials were encapsulated
with either solid water or HIPS to create a rigid and reproducible structure. Solid water
was used to encapsulate materials that were shown to previously chemically react to and
degrade HIPS. Due to the cost of solid water, materials that did not chemically react were
encapsulated with HIPS rather than solid water. The MRgRT inserts’ hard exterior shells
provided a rigid structure that could withstand hard shipping conditions.
Designing and manufacturing a motion system used for the MRgRT thorax
phantom was also included in Aim 3. The two MR safe motions systems considered for
the MRgRT thorax phantom was to use either a piezoelectric motor or a pneumatic
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system. MR safe piezoelectric motors were made with fragile ceramic materials that
usually had a limited workload capability. Since IROC-Houston equipment frequently
endures rough shipping and handling conditions it was not ideal to have a fragile motor
that could easily break during transit. A pneumatic system was an appropriate motion
system since it was durable and had a high workload capability. The pneumatic system
was designed with two major sections: MR safe and MR unsafe components (Figure 30).
The waveguide, built into all MRgRT suites, was used to separate the two sections. Thus,
MR unsafe components were positioned outside and the MR safe parts were positioned
inside the treatment room. The pneumatic system’s cylinder was an integral part of the
motion system since it needed to be MR safe and was positioned at the center of the
magnet. Commercially available aluminum cylinders were not completely MR safe since
most were manufactured with a stainless steel piston. An aluminum cylinder was bought
and the stainless steel piston was replaced with a custom made brass piston, thus,
allowing to be used in center of the MR bore.
After developing two phantoms in Aim 3, the MRgRT thorax and H&N phantoms
were irradiated and their dose deliveries were evaluated in Aim 4. Evaluations were done
by conducting a single institutional commissioning study and a multi-institutional
feasibility study. In these studies, TLDs and EBT3 films were used to compare the actual
treatment to anticipated treatment and were evaluated using the same criteria used in
IROC-Houston’s conventional phantoms. The passing criteria for the conventional
thorax and H&N phantoms were 7%/5mm and 7%/4mm, respectively. All studies passed
IROC-Houston’s criteria for the H&N (Table 15-Table 18) and thorax (Table 22-Table
25) phantom, thus demonstrating these phantoms were affective end-to-end QA tools
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which could be used to credential institutions participating in NCI-sponsored clinical
trials.
The simplistic breathing pattern from the pneumatic system could have been a
weakness in this work. The pneumatic system was designed such that every three seconds
the phantom would move into either exhale or inhale positions. While this pneumatic
system was used to represent lung breathing, it did not fully mimic breathing patterns
from a lung cancer patient. To fully mimic breathing patterns from a typical lung patient,
the pneumatic system would need to program a series of irregular lung movements. This
pneumatic system was IROC-Houston’s first MR safe motion system and was originally
designed with manual flow control knobs. The flow control knobs were physically
adjusted to create the speed at which the lung insert would move. These manual flow
control knobs could be replaced with programmable flow control knobs which could be
used to create various breathing patterns.
Another limitation of this work was the amount of institutions that participated in
the feasibility studies. These studies were restricted to MRgRT systems in the United
States, thus, reducing any time delays caused from shipping overseas and having to go
through customs. At the time of this study there were only a few MRgRT systems in the
United States which were fully installed and were working in the clinic. The feasibility
study consisted of institutions who initially agreed to participate in both phantom studies.
Some institutions, who had an MRgRT system, were not very receptive and either did
not provide all necessary items (i.e., exported treatment plan, reported dose) for the
evaluation studies, were undergoing an upgrade, was newly installed or had exported
corrupted treatment data that could not completely be analyzed. Since the Unity system
was new, only a handful of people were allowed to use the MRgRT system. The
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feasibility study did not include MD Anderson since the same person who was required
to operate the Unity system during the commissioning study was the same person who
would have completed the feasibility study. Despite the small cohort, the ones that did
participate in the feasibility studies passed IROC-Houston’s passing criterion.
The goal of the MRgRT thorax and H&N phantom was to evaluate each
institution’s complete MRgRT radiotherapy workflow. Every component of the multistep treatment workflow had an associated uncertainty. The purpose of the end-to-end
test was not to quantify or identify the source of each specific uncertainty but rather
evaluate the overall radiotherapy process. Based on the phantom irradiations, the end-toend feasibility studies demonstrated that the MRIdian

60

Co, MRIdian Linac and Unity

MRgRT systems could accurately deliver radiation plans. These studies also showed that
on-board MR imagers were able to verify treatment setup and track tumors on the
MRgRT phantoms. Lastly, the phantom’s irradiation performance did not show a vendor
dependence, thus demonstrating that the MRIdian and Unity systems can cohesively
deliver IMRT plans to treat the MRgRT phantoms.
The hypothesis of this project was that a homogeneous H&N and dynamic
heterogeneous thoracic anthropomorphic phantom could be designed to evaluate MRgRT
systems and would have agreements between the measured and calculated doses within
±7%/4mm and ±7%/5mm, respectively. Based on the information obtained from this
work the hypothesis was met by: 1) identifying tissue equivalent materials which were
MR/CT visible, 2) characterizing EBT3 and TLDs in the presence of a 0.35T and 1.5T
magnetic field 3) designing and manufacturing a homogenous H&N and a dynamic
heterogeneous thorax anthropomorphic MRgRT phantom and 4) performing a
commissioning and a feasibility study on both phantoms.
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6.2

FUTURE WORK
One potential avenue of future research would include modeling the MRIdian

treatment head more realistically. While the treatment head configuration on the MRIdian
60

Co system is proprietary, one could attempt to mimic the treatment head by applying

two MLCs within a generic 60Co Monte Carlo model. The user would have to estimate
the location of the two MLCs within the model. Even with approximate MLC locations
the simulated penumbra would better represent the actual penumbras seen on a MRIdian
system. Potentially, one could simulate the beam profiles better by using a phase-space
file provided by Viewray. While this would be the best scenario to simulate the MRIdian
beam profiles this would be more difficult to achieve since this would require
collaborating with ViewRay and asking them to provide the phase space data.
Another broad area of future work would include making several other
anthropomorphic phantoms for MRgRT systems. This future work could be completed
by either: making modification to IROC-Houston’s phantoms to adjust for the MR
component workflows or design new anatomical phantoms used for the MRgRT systems.
IROC-Houston currently has a conventional pelvis phantom that is only visible in CT.
This phantom could be constructed with materials suggested in the Steinmann et al. 2018
study to create an MRgRT pelvic phantom. Other anatomical phantoms could be created
using MRgRT materials. For example, an MRgRT pancreas phantom could be extremely
useful since ViewRay launched a multi-center prospective clinical trial for pancreatic
tumors.
Modifying the current MRgRT thorax phantom to address auto contouring and
online ART techniques could also be another future research area. Rather than having a
single insert, two inserts could be designed, manufactured and used in the credentialing
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process. The original insert would represent a patient’s tumor in the beginning of
treatment and the second insert would have a smaller PTV that represented the same
tumor after several fractionations. The original insert would have the same end-to-end
treatment methodology as the MRgRT thorax phantom and would be used to capture a
CT image, create an IMRT plan accordingly, verify a treatment setup using an MR
imager and irradiate the phantom. The second insert would be used to test automatic
contouring and online ART techniques. After the original insert was irradiated, it would
be removed and the second insert, with the smaller PTV, would be inserted into the
phantom. While the phantom was on the treatment couch, the institution would perform
their online ART workflow where they would have to auto contour the smaller PTV,
adjust the treatment plan, re-calculate the treatment plan, verify treatment plan and
irradiate the phantom with the new insert.
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Appendix A: Beam Profile
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Figure 34: Beam profiles generated under the geometrical head phantom 0T configuration
for the MRIdian beam. Averaged measured EBT3 beam profile compared to simulate beam
profiles on Monte Carlo.
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Figure 35: Beam profiles generated under the geometrical head phantom 0.35T
configuration for the MRIdian beam. Averaged measured EBT3 beam profile compared to
simulate beam profiles on Monte Carlo.
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Figure 36: Beam profiles generated under the geometrical lung phantom 0T configuration
for the MRIdian beam. Averaged measured EBT3 beam profile compared to simulate beam
profiles on Monte Carlo.
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Figure 37: Beam profiles generated under the geometrical lung phantom 0.35T
configuration for the MRIdian beam. Averaged measured EBT3 beam profile compared to
simulate beam profiles on Monte Carlo.
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Appendix B: Dose Profile
6.2.1

MRgRT Head & Neck: Left-Right

Unity 1-a: Right Left Profile
Left

Right
8

Dose (Gy)

6

4

2

Primary PTV

Secondary
PTV

0
-4

-3

-2

-1

0

1

2

3

4

5

6

7

8

Distance (cm)
Film

Institution Values

Figure 38: Left-right dose profile from Unity 1-a (7MV/1.5T) of the commissioning study
using the MRgRT H&N phantom.
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Figure 39: Left-right dose profile from Unity 1-b (7MV/1.5T) of the commissioning study
using the MRgRT H&N phantom.
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Unity 1-c: Right Left Profile
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Figure 40: Left-right dose profile from Unity 1-c (7MV/1.5T) of the commissioning study
using the MRgRT H&N phantom.
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Figure 41: Left-right dose profile from ViewRay2 (6MV/0.35T) of the feasibility study using
the MRgRT H&N phantom.
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ViewRay 3: Right Left Profile
8
Left

Right

Dose (Gy)

6

4

2

Primary PTV

Secondary
PTV

0
-4

-3

-2

-1

0

1

2

3

4

5

6

7

Distance (cm)
Film

Institution Values

Figure 42: Left-right dose profile from ViewRay3 (60Co/0.35T) of the feasibility study using
the MRgRT H&N phantom.
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6.2.2

MRgRT Head & Neck: Anterior-Posterior

Unity 1-a: Anterior Posterior Profile
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Figure 43: Anterior-posterior dose profile from Unity 1-a (7MV/1.5T) of the commissioning
study using the MRgRT H&N phantom.
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Figure 44: Anterior-posterior dose profile from Unity 1-b (7MV/1.5T) of the commissioning
study using the MRgRT H&N phantom.
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Unity1-c: Anterior Posterior Profile
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Figure 45: Anterior-posterior dose profile from Unity 1-c (7MV/1.5T) of the commissioning
study using the MRgRT H&N phantom.
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Figure 46: Anterior-posterior dose profile from ViewRay2 (6MV/0.35T) of the feasibility
study using the MRgRT H&N phantom.
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ViewRay 3: Anterior Posterior Profile
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Figure 47: Anterior-posterior dose profile from ViewRay3 (60Co/0.35T) of the feasibility
study using the MRgRT H&N phantom.
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6.2.3

MRgRT Head & Neck: Superior-Inferior

Unity 1-a: Superior Inferior Profile
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Figure 48: Superior-inferior dose profile from Unity 1-a (7MV/1.5T) of the commissioning
study using the MRgRT H&N phantom.
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Figure 49: Superior-inferior dose profile from Unity 1-b (7MV/1.5T) of the commissioning
study using the MRgRT H&N phantom.
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Unity 1-c: Superior Inferior Profile
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Figure 50: Superior-inferior dose profile from Unity 1-c (7MV/1.5T) of the commissioning
study using the MRgRT H&N phantom.
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Figure 51: Superior-inferior dose profile from ViewRay2 (6MV/0.35T) of the feasibility study
using the MRgRT H&N phantom.
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ViewRay3: Superior Inferior Profile
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Figure 52: Superior-inferior dose profile from ViewRay3 (60Co/0.35T) of the feasibility
study using the MRgRT H&N phantom.
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6.2.4

MRgRT Thorax: Left-Right Film Profiles
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Figure 53: Left-right dose profile from Unity 1-a (7MV/1.5T) of the commissioning study
using the MRgRT thorax phantom.
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Figure 54: Left-right dose profile from Unity 1-b (7MV/1.5T) of the commissioning study
using the MRgRT thorax phantom.

146

7

Unity 1-c: Left-Right Profile
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Figure 55: Left-right dose profile from Unity 1-c (7MV/1.5T) of the commissioning study
using the MRgRT thorax phantom.
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Figure 56: Left-right dose profile from ViewRay2 (6MV/0.35T) of the feasibility study using
the MRgRT thorax phantom.
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ViewRay3: Left-Right Profile
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Figure 57: Left-right dose profile from ViewRay3 (60Co/0.35T) of the feasibility study using
the MRgRT thorax phantom.
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6.2.5

MRgRT Thorax: Anterior-Posterior Film Profiles

Unity 1-a: Anterior-Posterior Profile
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Figure 58: Anterior-posterior dose profile from Unity 1-a (7MV/1.5T) of the commissioning
study using the MRgRT thorax phantom.
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Figure 59: Anterior-posterior dose profile from Unity 1-b (7MV/1.5T) of the commissioning
study using the MRgRT thorax phantom.
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Unity 1-c: Anterior-Posterior Profile
8
Posterio

Anterior

Dose (Gy)

6

4

2

PTV
0
-6

-5

-4

-3

-2

-1

0
1
Distance (cm)

Film

2

3

4

5

6

Institution values

Figure 60: Anterior-posterior dose profile from Unity 1-c (7MV/1.5T) of the commissioning
study using the MRgRT thorax phantom.
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Figure 61: Anterior-posterior dose profile from ViewRay2 (6MV/0.35T) of the feasibility
study using the MRgRT thorax phantom
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ViewRay3: Anterior-Posterior Profile
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Figure 62: Anterior-posterior dose profile from ViewRay3 (60Co/0.35T) of the feasibility
study using the MRgRT thorax phantom
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6.2.6

MRgRT Thorax: Superior-Inferior Film Profiles

Unity 1-a: Superior-Inferior Profile
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Figure 63: Superior-inferior dose profile from Unity 1-a (7MV/1.5T) of the commissioning
study using the MRgRT thorax phantom.
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Figure 64: Superior-inferior dose profile from Unity 1-b (7MV/1.5T) of the commissioning
study using the MRgRT thorax phantom.
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Unity 1-c: Superior-Inferior Profile
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Figure 65: Superior-inferior dose profile from Unity 1-c (7MV/1.5T) of the commissioning
study using the MRgRT thorax phantom.
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Figure 66: Superior-inferior dose profile from ViewRay2 (6MV/0.35T) of the feasibility study
using the MRgRT thorax phantom.
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ViewRay3: Superior-Inferior Profile
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Figure 67: Superior-inferior dose profile from ViewRay3 (60Co/0.35T) of the feasibility
study using the MRgRT thorax phantom.
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Appendix C: Gamma Analysis
6.2.7

MRgRT Head & Neck: Axial

Figure 68: The commissioning study for the MRgRT H&N phantom. Unity 1-a axial film
had 96.4% pixels passing.

Figure 69: The commissioning study for the MRgRT H&N phantom. Unity 1-b axial film
had 98.1% pixels passing.
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Figure 70: The commissioning study for the MRgRT H&N phantom. Unity 1-c axial film
had 99.1% pixels passing.

Figure 71: The feasibility study for the MRgRT H&N phantom. ViewRay 2 axial film had
97.9% pixels passing.
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Figure 72: The feasibility study for the MRgRT H&N phantom. ViewRay 3 axial film had
96.7% pixels passing.
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6.2.8

MRgRT Head & Neck: Sagittal

Figure 73: The commissioning study for the MRgRT H&N phantom. Unity 1-a sagittal film
had 89.9% pixels passing.

Figure 74: The commissioning study for the MRgRT H&N phantom. Unity 1-b sagittal film
had 89.9% pixels passing.
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Figure 75: The commissioning study for the MRgRT H&N phantom. Unity 1-c sagittal film
had 89.2% pixels passing.

Figure 76: The feasibility study for the MRgRT H&N phantom. ViewRay 2 sagittal film had
95.7% pixels passing.
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Figure 77: The feasibility study for the MRgRT H&N phantom. ViewRay 3 sagittal film had
96.6% pixels passing.
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6.2.9

MRgRT Thorax: Axial

Figure 78: The commissioning study for the MRgRT Thorax phantom. Unity 1-a axial film
had 89.0% pixels passing.

Figure 79: The commissioning study for the MRgRT Thorax phantom. Unity 1-b axial film
had 97.2% pixels passing.
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Figure 80: The commissioning study for the MRgRT Thorax phantom. Unity 1-c axial film
had 96.1% pixels passing.

Figure 81: The feasibility study for the MRgRT Thorax phantom. ViewRay 2 axial film had
96.8% pixels passing.
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Figure 82: The feasibility study for the MRgRT Thorax phantom. ViewRay 3 axial film had
93.1% pixels passing.
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MRgRT Thorax: Sagittal

Figure 83: The commissioning study for the MRgRT Thorax phantom. Unity 1-a sagittal
film had 90.4% pixels passing.

Figure 84: The commissioning study for the MRgRT Thorax phantom. Unity 1-b sagittal
film had 95.4% pixels passing.
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Figure 85: The commissioning study for the MRgRT Thorax phantom. Unity 1-c sagittal film
had 90.9% pixels passing.

Figure 86: The feasibility study for the MRgRT Thorax phantom. ViewRay 2 sagittal film
had 94.6% pixels passing.
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Figure 87: The feasibility study for the MRgRT Thorax phantom. ViewRay 3 sagittal film
had 92.5% pixels passing.
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